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A natural allelic series of complex structural variants and  
its influence on the risk of lupus and schizophrenia 
 
Abstract 
 
The human genome's strongest influences on two common diseases, systemic 
lupus erythematosus (SLE) and schizophrenia, arise from genetic variation in the Human 
Leukocyte Antigen (HLA) locus. However, the genes and functional alleles driving these 
genetic relationships have remained unknown. We hypothesized that a complex, multi-
allelic form of structural variation in the Complement component 4 (C4) gene, within the 
HLA locus, underlies these relationships.   
Loci that exist in many structural forms and vary widely in copy number have 
been difficult to analyze molecularly. As a result, we know little about their population 
genetic properties or their influence on phenotypes. In this work, we developed 
molecular and statistical methods to characterize such loci and to evaluate their 
contribution to phenotypes. 
Applying these methods to the C4 locus, we found that C4 segregates in four 
common and at least eleven low-frequency structural forms in human populations. 
Although there was only partial correlation between C4 structural variation and individual 
single nucleotide polymorphisms (SNPs), we developed an imputation approach to 
enable statistical prediction of C4 structural states from flanking SNP haplotypes.  
C4 structural variation associated to gene expression in lymphoblastoid cell lines 
and human brain tissue. Applying our imputation strategy to SLE and schizophrenia 
case-control cohorts totaling > 75,000 individuals, we found that structural variation in 
C4 contributes to risk of both phenotypes in a manner predicted by its effect on gene 
expression in relevant tissues, and with largely opposite directions of effect – alleles that 
were protective for schizophrenia increased risk for SLE, and vice versa. Leveraging a 
	   iv 
natural allelic series of C4 structural forms, we developed a novel form of association 
testing and showed that the association to C4 is unlikely to be caused by correlation with 
HLA SNPs. C4 was expressed in human neurons, whereas other upstream complement 
pathway genes were expressed primarily by microglia. Mice lacking C4 showed a deficit 
in synaptic pruning that was rescued by human C4. 
The methods developed in this thesis enable analysis of complex structural 
variation, and our results identify a novel form of genome variation as making a strong 
contribution to phenotypes.  
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Overview 
  Genome-wide association studies have identified thousands of genetic variants 
associated with human traits1. However, the functional variants responsible for driving 
the vast majority of these associations are largely unknown. Association of phenotypes 
to genetic markers in the Human Leukocyte Antigen (HLA) locus on chromosome 6 
represents a particularly challenging example of this problem. The HLA locus has been 
found to associate with dozens of autoimmune and infectious disease phenotypes, and it 
harbors the human genome's strongest influences on the risk of two phenotypes that are 
investigated in this thesis – systemic lupus erythematosus (SLE) and schizophrenia.  
  Genome-scale association studies of SLE, schizophrenia, and other complex 
phenotypes have so far ascertained only the simplest forms of genetic variation, whether 
rare or common: single nucleotide variation and simple deletions and duplications of 
genomic segments. However, a large and interesting class of genetic variation – 
complex and multi-allelic forms of structural variation – has yet to be rigorously 
investigated because of difficulties in analyzing it molecularly, and open questions 
remain: how do structurally complex loci vary across human populations? How can they 
be characterized molecularly and statistically? How can their contribution to phenotypes 
be investigated?  
  Complement component 4 (C4), a gene within the HLA locus, exhibits a complex 
form of structural variation, and in this thesis, we   
(i) developed molecular and statistical approaches to enable analysis of complex 
genome structural variation (Chapter 2); and   
(ii) applied these methods toward evaluating whether structural variation in C4 
contributes to the risk of SLE (Chapter 3) and schizophrenia (Chapter 4).  
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We begin by motivating and contextualizing the studies described in the chapters 
that follow.   
 
SLE and schizophrenia are complex diseases for which a better mechanistic 
understanding and new treatment options are needed  
 SLE 
Systemic lupus erythematosus is a chronic autoimmune disorder that affects 
multiple organ systems including skin, kidneys, brain, and blood, with a tendency to 
affect women of childbearing age. SLE has an estimated heritability of 66%2, a 
prevalence ranging from 20-150 cases per 100,0003, and it affects at least five million 
people worldwide. A diagnosis of SLE is made when any four out of eleven clinical 
criteria set by the American College of Rheumatology are met either serially or 
simultaneously, reflecting the clinical heterogeneity of the disease. Genetic and 
environmental factors resulting in immune system dysfunction with production of auto-
antibodies, immune complexes, and overactive B and T cells are thought to play a role in 
many of the symptoms of SLE, but the pathogenesis is not completely understood. 
SLE patients are typically treated with nonsteroidal anti-inflammatory drugs 
(NSAIDs), antimalarial drugs, glucocorticoids, and immunosuppressive agents 
depending on the specific organs involved. Despite the availability of these treatment 
options, most patients experience a relapsing and remitting course – complete remission 
for more than 5 years is rare (< 2% of patients)4 – and treatment can be associated with 
serious side effects such as bone marrow suppression and infections.   
 
Schizophrenia   
Schizophrenia is a disabling psychiatric disorder involving chronic or recurrent 
psychosis, with a typical age of onset in late adolescence to early adulthood. The 
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symptoms of schizophrenia can be grouped into three broad categories: positive 
symptoms (delusions, hallucinations, and disorganized thought and speech), negative 
symptoms (such as flat affect and poverty of speech), and cognitive symptoms 
(impairment in memory, attention, and executive function). Schizophrenia has a 
heritability estimated to be as high as 80%5, a lifetime prevalence of about 1%, and it 
affects at least 25 million people worldwide. The World Health Organization has ranked 
schizophrenia among the top ten illnesses contributing to the global burden of disease, 
based on Years Lost due to Disability (YLD)6, and schizophrenia is associated with a 
higher all-cause mortality compared to the general population7.  
Multiple antipsychotic medications exist for treating schizophrenia. However, the 
molecular targets of approved drugs in use for schizophrenia today are the same as 
those from more than 40 years ago8, reflecting the fact that the pathophysiology of 
schizophrenia is poorly understood. Less than 20% of schizophrenia patients remain 
relapse-free after experiencing their first psychotic episode9, and antipsychotic 
medications can cause significant side effects. Despite the need for the development of 
new treatment options, there has been an exodus of pharmaceutical companies away 
from drug development for psychiatric disorders in the recent years8.  
  
Genetic studies in humans can provide novel biological insights and identify new 
molecular drug targets 
While there is a strong need for new treatment options for SLE, schizophrenia, 
and many other diseases, the vast majority of candidate drugs that enter phase I clinical 
trials across multiple therapeutic areas are not successfully approved10. In most cases, 
the reason for the failure was not because the drugs did not act on the intended target, 
but they failed despite doing so; the therapeutic hypothesis regarding which targets 
would be efficacious and safe to perturb was incorrect in those cases11.  
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Studying the genetic basis of disease in humans has the potential to provide 
novel insights into the pathogenesis of disease12. For example, the role of the 
complement pathway in age-related macular degeneration (AMD) was not widely 
appreciated until one of the first genome-wide association studies (GWAS) identified an 
association to a polymorphism in complement factor H (CFH)13. Similarly, GWAS also 
implicated autophagy in the pathogenesis of Crohn's disease14. 
Human genetics can also serve as a valuable tool for identifying drug targets, 
and there are prospective as well as retrospective examples of this11. For example, 
linkage and sequencing studies led to the identification of a gain-of-function mutation in 
Proprotein convertase subtilisin/kexin type 9, (PCSK9) causing hypercholesterolemia15, 
a loss-of-function allele in the same gene in patients with low levels of low-density 
lipoprotein (LDL) cholesterol levels16, and a spectrum of other PCSK9 alleles 
contributing to LDL levels17. In phase I clinical trials, a monoclonal antibody to PCSK9 
significantly reduced LDL cholesterol in healthy subjects as well as those with 
hypercholesterolemia18. As another example, the identification of mutations in the 
sodium channel, voltage-gated, type IX, alpha subunit (SCN9A) gene in patients with a 
rare pain disorder19 and loss-of-function mutations in the same gene causing a 
congenital inability to feel pain20 has led investigators to develop drugs that block the 
gene product as a treatment for pain21. There are also retrospective examples in which 
human genetics has identified molecular targets for drugs that were already in use, as 
being important in disease. For example, a recent genome-wide association study of 
schizophrenia22 identified associations to dopamine receptor D2 (DRD2), which is the 
target of effective antipsychotic medications for schizophrenia. In addition, common 
variants in the 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) gene, the product of 
which is the target of statins, have been found to associate to blood lipid levels23.   
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The presence of a series of alleles within the same gene that contributes to a 
phenotype – as is the case with PCSK9 and SCN9A, described above – can be an 
extremely valuable tool that human genetic studies can deliver. Such an allelic series 
strengthens confidence in a gene's involvement in a disease, and can generate a 
genotype-phenotype dose-response curve11 that predicts the effect of modulating the 
gene's function on the phenotype. Along these lines, the following chapters in this thesis 
will describe the characterization of a natural allelic series of structural variants of the C4 
gene (Chapter 2), identification of its functional correlates, and evaluation of its role in 
clinical phenotypes (Chapters 3 and 4).  
  
Challenges in realizing the potential of genome-wide association studies to 
provide actionable insights  
While genome-wide association studies (GWAS) have identified thousands of 
genetic variants associating to human traits, there are analytical as well as experimental 
challenges in extracting actionable biological and therapeutic insights from these 
findings.  
Linkage disequilibrium (LD) blocks – regions of the genome containing SNPs 
whose genotypes are substantially correlated with each other – identified by the 
International HapMap Consortium24, allowed for 'tag SNPs' to be used for genotyping in 
GWAS, whereby a subset of common genetic variants being directly genotyped in an 
association study provides information about a larger set of common variants because of 
correlation between their genotypes. This very property that is useful in reducing the 
number of variants that needs to be experimentally genotyped has also made fine-
mapping challenging. GWAS-identified loci typically contain multiple genes, depending 
on the size of the LD blocks – and in the case of the HLA locus described below, it can 
span hundreds of genes. Within a locus, the variant that is most strongly associated to a 
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phenotype need not be the one that is causing the association (i.e., the 'causal variant'), 
for several reasons. First, because GWASs do not interrogate every genetic variant 
(common and rare), the observed association to variants that are evaluated can be 
driven by variants that are not analyzed in the study. Second, because of statistical 
fluctuation, the variant that is most strongly associated within a locus can change across 
studies and with increasing sample size. Third, in regions where multiple, independent 
effects on the phenotype exist, variants that underlie none of the effects can appear to 
associate strongly due to their correlation with those causally driving the association.  
Even after the genes and causal alleles implicated in a phenotype are identified, 
utilizing these findings toward gaining biological insights can be challenging. Most 
variants identified in GWAS are in non-coding regions of the genome25 (and many are 
not in LD with a protein-coding variant), in contrast to the highly penetrant, often protein-
altering mutations causing Mendelian diseases, and understanding their mechanistic 
and functional implications can be challenging. In addition, for diseases like 
schizophrenia, for which there are neither counterparts in model organisms nor robust 
molecular endophenotypes, it is also not clear which assays, cell types, or model 
systems to use toward studying the functional consequences of disease-associated 
genetic variants.  
  
Dozens of genetic risk loci have been identified for SLE and schizophrenia, but 
the functional alleles and their mechanistic implications remain largely unknown 
SLE  
Genome-wide association studies of SLE have identified more than 30 loci, 
which account for less than 10% of the genetic heritability. Among the variants that are 
most strongly associated within each locus, eleven are intergenic and ten are intronic26. 
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While the functional alleles and their mechanisms remain largely unknown, the 
likely causal variant and its functional consequences have been identified for at least 
one of these loci. A non-synonymous variant in the integrin, alpha M (ITGAM) was found 
to associate with SLE in European-Americans, Hispanic-Americans, and African-
Americans and to best explain the association of SLE to the ITGAM locus27. ITGAM is 
expressed mainly on myeloid cells, and one of its multiple ligands is iC3b, a proteolytic 
cleavage fragment of the central protein of the complement pathway. The SLE-
associated non-synonymous variant in ITGAM, rs1143679, was shown to cause 
impaired cell adhesion to iC3b and reduced iC3b-dependent phagocytosis28.  
Genes within SLE-associated loci fall into multiple pathways3: immune complex 
processing and innate immunity (to which genes of the complement pathway belong); 
dendritic cell function and interferon signaling; T-cell function and signaling; B-cell 
function and signaling; cell cycle, apoptosis, and cellular metabolism; and transcriptional 
regulation. Some of the loci associated with SLE have also been implicated in other 
autoimmune diseases, whereas other loci appear to be unique to SLE. For example, the 
STAT4 (signal transducer and activator of transcription 4) locus has also been implicated 
in inflammatory bowel disease29, and Sjogren's syndrome30. Likewise, the TNFAIP3 
(tumor necrosis factor alpha induced protein 3) locus is also associated with rheumatoid 
arthritis31, celiac disease32, and psoriasis33, in addition to SLE. However, other loci, 
including ITGAM and SLC15A4 (Solute carrier family 15, member 4), do not have known 
associations to other autoimmune phenotypes from genome-wide association studies26. 
Overall, a comprehensive analysis of shared loci between SLE and seventeen 
autoimmune phenotypes found limited genetic overlap outside of the HLA locus34. This 
relatively distinct genetic susceptibility for SLE compared to several other autoimmune 
diseases raises the question of to what extent SLE would be considered an autoimmune 
phenotype based on its genetic risk factors if it did not associate to the HLA locus.  
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 Schizophrenia   
Over the past few years, various types of genetic analyses – studies of rare copy 
number variation, genome-wide association studies, and exome sequencing studies – 
have provided insights into the genetic architecture of schizophrenia and have shown 
that genetic variants of all sizes and frequencies contribute to the risk of schizophrenia.  
Results from common variant as well as rare variant studies have taught us that 
schizophrenia is a highly polygenic disorder – its risk is likely influenced by a very large 
number of genes, each contributing a small effect. In 2009, Purcell and colleagues35 
developed the concept of polygenic risk score, whereby they calculated an aggregate 
score by quantifying variation across nominally associated loci and provided evidence 
that the risk of schizophrenia is influenced by thousands of common alleles of small 
effect. A recent exome sequencing study of schizophrenia36 provided additional support 
for the polygenic model by demonstrating that rare, disruptive mutations were distributed 
across many genes. Earlier findings of an increased genome-wide burden of rare copy 
number variants in schizophrenia37 are also consistent with the polygenic nature of the 
disorder.  
Genetic risk loci associated to schizophrenia have also been implicated in other 
neuropsychiatric disorders, both adult- and childhood-onset. The polygenic component 
contributing to schizophrenia also influences risk of bipolar disorder, but not other, non-
psychiatric diseases35. In an analysis of genome-wide pleiotropy between schizophrenia 
and four other psychiatric disorders (bipolar disorder, major depression, autism spectrum 
disorder, and attention deficit hyperactivity disorder) based on genetic correlation 
quantified using common variants, schizophrenia was shown to have the highest co-
heritability with bipolar disorder among the phenotypes studied38.  A joint analysis of 
these five psychiatric disorders identified associations to four loci, two of which were to 
voltage-gated calcium channel subunits39. The sharing of risk loci across neuro-
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psychiatric disorders has also been appreciated from studies of rare copy number 
variation. For example, duplication of the 16p11.2 locus is associated with 
schizophrenia, bipolar disorder, and autism, and deletions of the same locus are 
associated with autism and developmental disorders40.  In addition, rare, recurrent 
deletions of the 1q21.1 locus are associated with schizophrenia37 and duplications of the 
same locus have also been described in patients with autism41.    
A recent, large GWAS of schizophrenia22 identified 108 associated loci and 128 
statistically independent effects within these loci. The associated regions included 
multiple subunits of the L-type voltage-gated calcium channels and genes involved in 
glutamatergic neurotransmission, both of which have also been implicated by studies of 
rare variants36, 42 . Among the 108 loci, the physical boundaries of which were delimited 
by SNPs whose correlation to the most strongly associated variant in the region was an 
r2 ≥ 0.6, 17 had no known genes within the boundaries, 45 had a single gene, 11 had 2 
genes, 26 had between 3 and 10 genes, and 9 had more than 10 genes. Of these, the 
locus that was least well mapped was the HLA locus, where the association signal 
spanned dozens to hundreds of genes.  
  
The HLA locus harbors the genome's strongest influences on the risk of SLE and 
schizophrenia, but the association is complex and unsolved  
The HLA locus stands out among the loci associated with SLE and schizophrenia 
from genome-wide association studies, both in terms of strength of association and 
effect size (Figure 1.1), and this association is well replicated in both phenotypes43-49. 
However, the gene(s) and functional allele(s) within the HLA locus driving the 
association to these phenotypes have not been identified, nor is the reason for the 
seemingly outsized strength of association to the HLA locus known.  
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Figure 1.1. The HLA locus harbors the variant(s) most strongly associated to SLE and 
schizophrenia. -log10(p) (strength of association) is plotted against odds ratio (effect size) 
for the risk allele of the most strongly associated variant from each locus that surpasses 
the threshold for genome-wide significance, 5x10-8 in (a) SLE43 and (b) schizophrenia22.  
  
The HLA locus is an extensively investigated region of the human genome, 
owing to its interesting and complex population genetic properties, and its influence on 
dozens of autoimmune and infectious disease phenotypes. The extended HLA locus 
spans approximately 8 megabases on human chromosome 6, from 26 Mb to 34 Mb. 
Although the region is referred to as the 'HLA  locus', it contains hundreds of genes, only 
a small fraction of which encode for classical HLA molecules that are involved in 
presenting antigens to cells of the immune system50. Indeed, members of diverse gene 
families, including 3 complement genes – C4, complement factor B (CFB), and C2 – and 
genes encoding tRNAs, histones, and olfactory receptors, make up the majority of genes 
in this locus.  
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The HLA locus is characterized by strong and long-range LD, whereby the 
genotypes of variants at distances of even 1-2 Mb or greater are strongly correlated with 
each other51. As a result, markers spanning a large number of genes can have similar 
strengths of association to phenotypes. The HLA locus is also highly polymorphic, with 
at least eight common haplotypes52, 53. The extensive, long-range LD, high gene- and 
polymorphism-density have all contributed to the difficulty in fine-mapping associations 
of this locus to phenotypes.  
The association of the HLA locus to SLE spans a few dozen genes, over 
approximately a 2 Mb distance (Figure 1.2a). The locus appears to harbor multiple 
independent effects on SLE44, 54 and classical alleles of the HLA-DRB1 gene, 
DRB1*03:01 and DRB1*15:01 have been consistently implicated in SLE55, 56. In a joint 
analysis of classical HLA alleles and SNPs in non-HLA genes, the association to the 
HLA locus was proposed to be best explained by a combination of multiple alleles in 
HLA genes as well as in non-HLA genes54. The C4 locus, in particular, has also been 
extensively investigated as a risk factor for SLE, although the contribution of the full 
extent of structural variation in C4 has not been studied in the manner described in 
Chapter 3. While complete deficiency of C4 (rare) is one of the strongest risk factors for 
SLE57, the results with respect to the contribution of common forms of copy number 
variation in C4 have been conflicting. Some studies have reported an association to 
SLE58, 59, whereas others have concluded that C4 does not contribute to SLE 
independently of HLA classical alleles60 and it remains unclear whether the apparent 
association of C4 to SLE is due to LD with variation in HLA classical genes.  
The association of the HLA locus to schizophrenia (Figure 1.2b), as with SLE, is 
complex and unsolved, and is characterized by the following properties. First, the 
strength of the association to this locus is much greater than to other loci identified from 
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Figure 1.2. Association of the extended HLA locus to (a) SLE and (b) schizophrenia. 
The SLE association data are from 2,390 cases and 8,707 controls of European 
ancestry, and the schizophrenia data are from 28,799 schizophrenia cases and 35,986 
controls (described in further detail in Chapters 3 and 4). The dashed red line represents 
the genome-wide significance threshold (p = 5x10-8). The annotations below the x-axis 
indicate the genes within the extended HLA locus, with at least dozens of genes within 
the span of the association signals in each phenotype.  
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GWAS (Figure 1.1b). Second, the association signal spans several megabases and 
dozens to hundreds of genes. Third, no single variant within the locus is sufficient to 
explain the entire signal – there appear to be multiple, independent effects, as in SLE. 
Fourth, the location of the most highly associated variant within the HLA locus across 
multiple studies has spanned more than 3 Mb35, 47, 48, 61.  
 The association of the HLA locus to schizophrenia has been a topic of 
investigation and discussion since 197462. Dozens of studies have tested for association 
of classical alleles of HLA genes to schizophrenia63, with some reporting associations to 
specific alleles. However, such associations could be the result of LD to variants in non-
HLA genes and even genes that do not function in the immune system. Furthermore, 
many of these studies were plagued by the same problems that characterized many pre-
GWAS candidate gene association studies – small sample sizes, lack of sufficiently 
stringent statistical thresholds, spurious associations due to population stratification, and 
questionable genotyping accuracy64. Nevertheless, consistent associations to the HLA 
locus, if not to specific alleles within HLA genes, have been found by genome-wide 
association studies as well35, 47, 48, 61.  
 Some of the hypotheses for why a neuropsychiatric phenotype associates to a 
locus that is enriched for immune genes have focused on the possible involvement of 
the classical HLA molecules. The higher risk of schizophrenia in individuals born during 
late winter or early spring months65, when there is an increased occurrence of certain 
infections, has led to the notion that schizophrenia may have an infectious trigger. 
Prenatal infections have been associated with an increased risk of schizophrenia66, and 
it has been hypothesized that the immune response to an infection during susceptible 
periods of gestation, modulated by genetic variation in HLA genes, may influence 
neurodevelopment and predispose to later developing schizophrenia. The hypothesis 
that schizophrenia may be an immune-mediated disease has been supported by the 
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increased risk of schizophrenia in individuals with a history of autoimmune diseases67, 
by reports of auto-antibodies against neurotransmitter receptors in some patients68, 69, 
and by studies investigating levels of inflammatory cytokines in patients with 
schizophrenia70. More recently, a role for classical HLA molecules in the developing 
nervous system has been appreciated71-74, suggesting that their potential involvement in 
schizophrenia may be independent of their function in the immune system.  
A few studies have specifically investigated the C4 locus for its contribution to 
schizophrenia75-77. However, these studies were performed without consideration of 
variation in the HLA locus outside of C4 (which, because of the extensive LD in the 
region, is critically necessary to evaluate), their samples sizes were considerably (1-2 
orders of magnitude) smaller than current genetic studies of schizophrenia, and the 
results were conflicting.  
 
Complex forms of genome structural variation are not well understood  
As recently as a decade ago, the extent to which genome structural variation – 
variation in copy number, length, orientation, genomic location of DNA segments – at 
sub-microscopic scales contributes to germline genetic variation among humans was 
unknown. Early studies of copy number variation (CNV)78, 79 suggested that human 
genome structure is more dynamic than previously appreciated, and since then, we have 
learned that copy number variation affects as many nucleotides in the human genome 
as single nucleotide variation80, it is heritable81, and can contribute to disease risk37, 40, 82, 
83. 
Simple forms of structural variation, such as bi-allelic deletions (Figure 1.3a) and 
duplications, in which a locus segregates in only two different forms, have been well 
characterized. Existing approaches for measuring copy number such as quantitative 
16 	  
 
Figure 1.3. A schematic example of (a) simple copy number variant (CNV) and (b) a 
complex CNV. In this example, the simple CNV has two alleles and three possible 
genotypes; the complex CNV has four alleles and ten possible genotypes. The number 
below the genotypes indicates the copy number that would be measured per diploid 
genome, given each genotype. Note that, for a complex CNV, multiple combinations of 
alleles can give rise to the same diploid copy number.  
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PCR (qPCR) and oligonucleotide arrays have been successfully used for molecular  
analysis of simple forms of copy number variation84. Simple CNVs are part of catalogs of 
human genetic variation85, 86, and their population genetic properties have been 
described – most common deletions are ancestral mutations that segregate on specific 
SNP haplotypes84, 87. In addition, the contribution of both rare and common forms of 
simple CNVs to clinical phenotypes has been investigated37, 40, 82, 83. 
In contrast, structurally complex loci are not well understood. We define 
structurally complex loci as those segregating in more than two (and often many more 
than two) structural forms. A locus can be structurally complex if multiple structural 
features such as copy number variation, variation in length of the locus, and multiple 
paralogous forms are present at the same locus (as is the case with C4, described in 
Chapter 2). Even when the only structurally variable feature of a locus is its copy 
number, multi-allelic variation in copy number can give rise to structural complexity 
(Figure 1.3b). Without molecular or statistical methods for characterizing such loci 
accurately, they have not been characterized in catalogs of genome variation and their 
contribution to clinical phenotypes has not been extensively investigated. Even in cases 
where association between complex CNVs and clinical phenotypes has been evaluated, 
lack of reproducibility has raised doubts about the accuracy with which these CNVs were 
measured88-91.  
The challenge in molecular ascertainment of multi-allelic CNVs is acknowledged 
in current literature92, 93. Distinguishing between a wide range of copy numbers such as 
0-10 is a difficult signal-to-noise problem that approaches such as qPCR are often 
inadequate for. For example, while qPCR may be able to readily distinguish between 0, 
1, 2, and 3 copies, distinguishing between 4 and 5 copies is more challenging as it 
represents a smaller fold-change in copy number that requires greater precision and 
sensitivity. In addition, determining allelic states of multi-allelic CNVs can be complex 
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because multiple combinations of alleles can give rise to the same diploid copy number 
that is measured in a molecular assay (Figure 1.3b). To this end, we describe, in 
Chapter 2, molecular and statistical approaches that enable accurate measurement of 
copy number of multi-allelic CNVs and determination of their allelic states.  
Several factors motivate the study of complex forms of genome structural 
variation. First, multi-allelic CNVs affect the dosage of hundreds of genes94, and have 
been estimated to be five times more likely to contain protein-coding genes than simple 
deletion CNVs95, suggesting that they may be a functionally important class of genetic 
variation. Second, because of the wider range of variation that affects loci segregating in 
multiple structural forms, the effect that such loci can have on phenotypes (and the 
power to detect association to them) has the potential to be greater. Third, by definition 
of structurally complex loci segregating in more than two alleles, their correlation to 
individual SNPs, which are bi-allelic, can be only partial. This has two implications: (i) to 
the extent that it is poorly tagged by individual SNPs that are tested for association in 
GWASs, such variation is interrogated neither directly nor indirectly in current 
association studies – accurately genotyping complex structural variants in GWAS data 
sets therefore has the potential to generate novel associations; and (ii) the partial 
correlation between complex CNVs and SNPs yields greater power in analyses of 
conditional association to evaluate the primary source of the association signal, which 
for regions like the HLA locus that are characterized by extensive LD, is especially 
valuable. Fourth, an association of a phenotype to a series of multiple structural alleles 
in the same gene provides confidence in the involvement of that gene in a phenotype (as 
we will demonstrate in Chapters 3 and 4). 
 
C4 functions in the complement pathway, which has dual roles in the immune and 
nervous systems  
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The complement system derives its name from its ability to complement other 
components of the immune system in mounting an immune response. It consists of more 
than thirty proteins that protect against damage by pathogens, immune complexes, and 
cellular debris. There are three pathways to activation of the complement cascade, each 
involving different types of triggers – classical, alternative, and lectin pathways. The 
classical pathway is triggered when antibodies bind to microbes or other antigens, and 
the first component of the classical pathway, C1q, recognizes this immune complex. The 
alternative pathway is triggered when complement proteins are directly activated by 
antigens on the microbial surface. The lectin pathway is activated when mannose-
binding lectin (a plasma protein) binds to mannose residues on microbes. While the 
early steps of activation differ across the three pathways, they all converge on the 
proteolytic activation of the central component of the pathway, C3, into its major 
fragment, C3b.  
The complement cascade has three primary functions in host defense. First, C3b 
serves as an opsonin – it coats microbes and antigens and promotes their binding to 
C3b receptors, such as complement receptor 1 (CR1), on phagocytic cells. Second, 
activated fragments of complement such as C3a and C5a serve as chemo-attractants, 
which recruit inflammatory cells to the site of complement activation. Third, if the 
activation of complement progresses to its terminal stage, a membrane attack complex 
(MAC) is formed, which forms pores on cell membranes, resulting in osmotic lysis and 
cell death.  
C4 plays an important role in the classical pathway of the complement system 
(Figure 1.4). Upon activation by a complex of C1 proteins, it forms an enzymatic 
complex, together with the activation product of C2. This complex, called the C3 
convertase, produces C3b from C3. There are two primary activation fragments of C4, 
C4a and C4b (not to be confused with C4A and C4B, which refer to different paralogous  
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Figure 1.4. Classical complement pathway. The classical complement pathway is 
triggered by the binding of C1q to antibodies, which are in turn bound to antigens. The 
C1 complex activates C2 and C4, and their activated fragments form the C3 convertase, 
which binds covalently to the antigen. The C3 convertase activates the central 
component of complement, C3. C3b covalently binds the antigen and serves as an 
opsonin to enhance phagocytosis by cells that express receptors for C3b. In addition, 
C3b also forms part of the C5 convertase, which activates C5. The late steps of the 
complement pathway lead to formation of the Membrane Attack Complex (MAC), which 
inserts into cell membranes, causing osmotic lysis and cell death. In studies detailed in 
Chapter 4, we investigated the expression, in postmortem human brains, of many of the 
genes shown in this figure – C1q, C2, C3, C4, and CSMD1.  
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Figure 1.4 (continued) 
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forms of the C4 gene, described in Chapter 2). C4a serves to stimulate inflammation and 
C4b, in addition to being a component of the C3 convertase complex, may also serve as 
an opsonin96. C4 also plays a role in maintaining immune tolerance by regulating 
elimination of self-reactive B cells97.  
Membrane-bound as well as plasma proteins of the complement system serve 
important regulatory roles in preventing damage to the host organism that may otherwise 
result from the activation of complement. One of these regulatory complement proteins 
is CSMD1 (CUB and Sushi multiple domains 1), an inhibitor of the classical complement 
pathway98 that promotes degradation of C4b and C3b99. C4 binding protein is another 
regulatory protein, and it binds to C4100 and interferes with the assembly of the classical 
pathway C3 convertase. 
The complement pathway may be involved in the pathogenesis of SLE at 
multiple levels, with both beneficial and detrimental effects101. Deficiency of the early 
components of the complement pathway such as C1q and C4 have been causally 
implicated in the development of SLE102, consistent with the fact that these complement 
components play a role in the clearance of necrotic debris101 (thereby preventing it from 
acting as a source of auto-antigens) and in maintenance of self-tolerance103. However, 
complement may also be involved in mediating tissue damage – auto-antibodies can 
trigger activation of the classical complement pathway, leading to inflammation and cell 
injury. Levels of complement proteins in the serum are used clinically to track disease 
activity and severity in SLE, and patients typically have low levels of complement  
proteins. However, this observation alone does not clarify the role of complement in SLE 
as low levels could be a result of a genetic deficiency and/or consumption of 
complement during disease progression. 
While functions of the complement pathway in the immune system have been 
appreciated for decades, an important role for the pathway in the nervous system has 
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come to light in just the past few years. In 2007, Stevens and colleagues showed that 
C1q and C3 are necessary for synaptic pruning, a process by which excessive and 
under-utilized synapses are eliminated during development of the central nervous 
system104. More recently, this process was shown to be mediated by microglia in a 
complement- and neuronal activity-dependent manner105. Genetic studies have also 
pointed to a role for complement in the nervous system – genome-wide association 
studies of Alzheimer's disease have identified associations to CR1, which encodes a 
receptor for C3b and C4b, and CLU, which serves as an inhibitor of the complement 
pathway106 (among its other functions).  
The dual roles of the complement pathway in the immune and nervous systems 
raise the question of what the contributions of genes in this pathway are to disorders of 
the respective systems. More specifically, the strong, yet unexplained nature of the 
association of the HLA locus to SLE and schizophrenia – among other factors, 
discussed in Chapters 3 and 4 – motivates an investigation of whether C4, within the 
HLA locus, contributes to these phenotypes. Such an investigation, however, would 
require the development of new approaches to characterize complex structural variation 
and to make such variation accessible to association analysis. We proceed in the 
following chapter by describing these approaches.  
 
	   
  
 
 
 
 
 
 
 
 
Chapter 2 
Molecular and population genetics of the  
human complement component 4 (C4) locus 
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The human C4 gene exhibits a complex form of structural variation 
Complement component 4 (C4), in the HLA locus, is one of the most polymorphic 
genes in the human genome, harboring multiple forms of genetic variation (Figure 2.1). 
First, there is variation in the number of copies of the C4 gene (Figure 2.1a), with a 
diploid genome typically containing 2-6 copies. Second, a length polymorphism gives 
rise to a long (C4L) and short (C4S) form of the gene (Figure 2.1b). This polymorphism 
is due to an insertion of a ~6.4 kb Human Endogenous Retroviral (HERV) sequence that 
is present in intron 9 of C4L but absent in C4S107. The HERV element is present in an 
opposite orientation to that of the C4 gene, and because it has accrued many protein-
disrupting mutations since the time of insertion, it is not thought to encode functional 
proteins. However, the HERV element contains sequences that may be transcriptionally 
active, such as TATA boxes and an SV40-type enhancer sequence. Third, sequence 
variants clustered in exon 26 define two paralogous forms of the gene, C4A and C4B 
(Figure 2.1c). Despite the high sequence similarity between the two paralogs, they have 
different biochemical properties108. C4A has a higher affinity for amino groups (such as 
those found in proteins, including immune complexes), whereas C4B has higher affinity 
for hydroxyl groups (such as those found in bacterial carbohydrate antigens). All four 
combinations of C4 structural features exist – AL, AS, BL, and BS – and each of these 
forms varies in copy number.  
Variation of this nature has not been investigated in genome-wide association 
studies (GWAS) or exome sequencing studies, so its relationship to phenotypes is not 
well characterized. Such variation is also absent from catalogs of human genetic 
variation such as the HapMap24 and 1000 Genomes Projects86, and we do not 
understand its population genetic properties.  
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Figure 2.1. Structurally variable features of the C4 locus. (a) The number of C4 genes is 
variable, with typically 1-3 per chromosome. (b) A Human Endogenous Retroviral 
(HERV) sequence is present in the long form of the C4 gene (C4L) and is absent in the 
short form (C4S). (c) There are two paralogous forms of C4, C4A and C4B, which are 
defined by nucleotide differences in exon 26 of the gene.  
 
Strategy for characterizing complex genome structural variation  
Our approach for characterizing structural variation in C4 is summarized in 
Figure 2.2 and is described in detail in the remaining sections of this chapter. We first 
determined the copy number of each C4 structural form (AL, AS, BL, and BS) per diploid 
genome, in a set of father-mother-offpsring trios of European ancestry (HapMap CEU 
sample). Next, we inferred the copy number of each C4 form per chromosome, based on 
diploid copy number, allele frequencies, and inheritance in trios. We then defined C4 
structural haplotypes – combinations of C4 structural forms that segregate together on 
the same chromosome – based on co-transmission of these forms in trios. We jointly 
phased these C4 structural haplotypes with haplotypes of SNPs in the HLA locus in 
order to evaluate the relationship between the two. By creating these integrated 
haplotypes of C4 structural variation and SNPs, we generated a reference panel, which 
we then tested for its ability to impute (statistically predict) C4 structural states using 
existing SNP genotype data.  
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Figure 2.2. Strategy for characterizing complex structural variation in C4. Each of these 
steps is discussed in detail in the text. 
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A droplet-based PCR approach enables precise molecular analysis of the C4 locus 
 
Existing methods for measuring copy number variation are inadequate for molecular 
analysis of C4 structural variation  
Oligonucleotide microarrays have been used successfully to measure copy 
number of simple CNVs80, 84, in which the amount of signal generated by genomic DNA 
segments binding to probes on a microarray is used to infer copy number. We 
considered the ability of these arrays to be used for measuring copy number of C4 
structural features. However, commonly used genotyping arrays lack probes in 
informative locations to detect specific C4 features (Figure 2.3a). We then evaluated 
whether quantitative PCR (qPCR), another approach commonly used to measure copy 
number variation, can yield integer copy numbers for the C4 CNVs. We used reaction 
conditions and assays that were based on qPCR assays previously reported to yield 
accurate copy number measurements of the C4 CNVs109, and we compared the 
measurements to results from Southern blot analysis (considered to be the gold 
standard for determining C4 copy number), of the same samples performed by another 
study110. Although the measurements from qPCR were correlated with the expected 
copy number, they did not resolve into clusters, and confident assignment of copy 
number genotypes was not possible for most of the samples (Figure 2.3b).  
While Southern blot analysis could be used to determine copy number, it would 
not provide the throughput needed to genotype C4 CNVs in a large number of samples. 
Therefore, we turned to a new approach, droplet-digital PCR, for measuring copy 
number of C4 structural features.  
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Figure 2.3. (a) Location of probes within C4A and C4B genes on commonly used 
oligonucleotide microarrays, Affymetrix 5.0, Affymetrix 6.0, and Illumina Human 
OmniExpress (the former two do not contain any probes within the C4 gene). (b) Copy 
number estimates for C4A (left) and C4B (right) from qPCR based on triplicate 
measurements plotted against copy number determined by Southern blot analysis for 
the same samples by Fernando et al110.  
  
Droplet-digital PCR (ddPCR) yields integer copy number measurements of the C4 
CNVs  
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We measured copy number of each C4 structural feature – A, B, L, and S – using 
a new molecular approach, droplet-digital PCR (ddPCR)111 (Figure 2.4) in 180 
individuals from the HapMap CEU sample of European ancestry24. ddPCR involves 
partitioning of a standard real-time PCR reaction mixture consisting of primers and 
fluorescent probes that are directed to the target (copy number variable) locus as well as 
to a copy number-invariant reference locus (Figure 2.4a), into thousands of nanoliter-
sized droplets. A restriction digest of the DNA prior to the generation of droplets is 
performed to separate multiple copies of the same locus that are in tandem (as is the 
case with the C4 locus) and allow independent segregation of the template into droplets. 
Droplet generation produces micro-droplets that are uniform in size (Figure 2.4b) and 
that compartmentalize the PCR reaction, such that each droplet contains zero, one, or 
very few copies of the template from each locus. The higher the copy number of a locus, 
the greater the number of droplets that contain a PCR template for it. PCR amplification 
occurs within the droplets and an end-point fluorescence measurement is taken for each 
of the two fluorophores from each droplet. This resolves the droplets into four classes: (i) 
FAM-VIC-, (ii) FAM-VIC+, (iii) FAM+VIC-, and (iv) FAM+VIC+ (Figure 2.4c). Variation in 
copy number is reflected in the fraction of droplets that are positive for the template, as 
opposed to differential kinetics of amplification as in qPCR. Also in contrast to qPCR, 
ddPCR provides absolute quantification because applying Poisson correction to the 
fraction of positive droplets (to account for droplets that contain more than one copy of 
the template) yields an estimate of the number of copies of the template per droplet. 
Once the absolute number of copies of the target (CNV) locus and reference (two-copy) 
locus are calculated, the ratio between the two is used to determine absolute copy 
number of the CNV locus per diploid genome.  
Applying this approach to the C4 locus, we were able to resolve integer copy 
numbers of each of the C4 structural features, across a range of 0-5 copies per diploid 
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Figure 2.4. Droplet-digital PCR (ddPCR)111. (a) Each assay involves simultaneous PCR 
amplification of two loci – the CNV locus and a control, two-copy locus. (b) The reaction 
mixture is partitioned into thousands of nanoliter-sized droplets (Image source: Bio-Rad 
Laboratories). (c) Following PCR, FAM and VIC fluorescence are analyzed in each of 
the microdroplets by a droplet reader, and four classes of droplets are observed: (i) 
FAM-VIC-, (ii) FAM-VIC+, (iii) FAM+VIC-, (iv) FAM+VIC+. The fraction of droplets that 
are positive for the template is Poisson-corrected to estimate the absolute number of 
copies of the template in the reaction. The ratio between the number of template copies 
from the CNV locus and the reference locus is used to determine absolute copy number 
of the CNV locus per diploid genome.  
 
genome (Figure 2.5).  In a set of 180 HapMap CEU samples, each C4 feature had multi-
allelic variation in copy number, with a range of 0-5 copies per diploid genome of C4A, 0-
3 copies of C4B, 1-5 copies of C4L, and 0-3 copies of C4S. Given that ddPCR is a new 
approach, we sought to evaluate the accuracy of the copy number measurements 
generated using this method. First, we checked for internal consistency across the four 
copy number measurements for each sample – if one of the measurements was 
incorrect, then the expectation that the number of copies of C4A + C4B = C4L + C4S, 
would not be met. Indeed, across all of the samples we typed, this relationship was 
confirmed. However, if a sample had more than one incorrect measurement (e.g., if the  
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Figure 2.5. Copy number of C4 structural features per diploid genome as determined by 
ddPCR. Representative results from measuring copy number of (a) C4A, (b) C4B, (c) 
C4L, and (d), C4S in HapMap CEU samples are shown. The genomes analyzed (x-axis 
values) are sorted from left to right by their copy number measurement, and the absolute 
copy number, with 95% Poisson confidence intervals, is on the y-axis. Note not only that 
there is separation between samples with different copy numbers, but also that the point 
estimates fall at an integer value for the vast majority of the samples.  
 
copy number of both C4A and C4L in a given sample were incorrectly measured to be 
one less than the actual copy number), then it is possible for the data to still appear 
internally consistent. Therefore, we evaluated the accuracy of our ddPCR results by also 
comparing them to data from orthogonal approaches. First, we compared our copy 
number measurements for C4A and C4B to those generated by Fernando et al. using 
Southern blot analysis of the same samples110. Across 89 samples that had 
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measurements from both approaches, there was 100% concordance for both C4A and 
C4B copy number. We next compared the measurement of C4L copy number using 
ddPCR to that calculated from an approach based on read-depth analysis of whole-
genome sequence (WGS) data85. This computational approach, Genome STRucture in 
Populations (Genome STRiP), has been used successfully to generate high-confidence 
measurements of copy number in another structurally complex locus112. Genome STRiP 
exploits the fact that read depth across a genomic segment is a measure of its copy 
number, once technical influences, uniqueness, and alignability of the local sequence 
are accounted for. Across 64 samples for which we generated copy number 
measurements using ddPCR as well as Genome STRiP (using low-coverage WGS data 
from the 1000 Genomes Project) 61 (95.3%) were concordant. 
  
Long-range relationships between C4 structural features can be inferred using ddPCR 
While the experiments described above allowed determination of the number of 
copies of C4A, C4B, C4L, and C4S per diploid genome, they did not reveal the copy 
number of the compound C4 structural forms – AL, AS, BL, and BS. In other words, for a 
given C4 gene, long-range relationships between the L/S and A/B defining molecular 
features (separated by ~5 kb in a short C4 gene and ~11.5 kb in a long C4 gene) would 
need to be determined. Our strategy was to determine whether the rarest form of the C4 
gene, C4AS, was present in each genome, and then use the following relationships to 
calculate the diploid copy number of the other three forms of the C4 gene (AL, BL, and 
BS):  
Copy number (CN) of C4AL = (CN of C4A) - (CN of C4AS)  
CN of C4BL  = (CN of C4L) - (CN of C4AL) 
CN of C4BS  = (CN of C4B) - (CN of C4BL)   
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The above relationships between the copy number of different C4 structural features 
hold true because any given C4 gene is defined by its length (long or short) and its 
paralogous form (A or B).  
  We developed a ddPCR-based approach in order to determine whether a given 
genome contained a C4AS gene. This approach exploits the fact that, when assaying for 
two different segments of DNA (i.e., the sequences that define the C4A and C4S 
features), the fraction of droplets that are positive for DNA templates containing both 
segments (double-positive droplets) should be a function of the fractions that are positive 
for only one of the two, at low concentrations of input DNA. This expectation would be 
met if the two segments of DNA being assayed are unlinked – i.e., able to segregate into 
droplets independently of each other. However, under a scenario in which the C4A and 
C4S features were present on the same DNA template (indicating the presence of a 
C4AS gene), this would result in an enrichment of double-positive droplets.  
We first performed long-range PCR to enrich for DNA templates that spanned the 
L/S and A/B assay sites. The forward primer was placed upstream of the HERV 
sequence and the reverse primer, downstream of the A/B defining sequence so that 
every form of the C4 gene (AL, AS, BL, and BS) would be amplified. We then used this 
long-range PCR product as input into ddPCR, with one assay specifically interrogating 
the presence of C4A and the other, C4S. Representative results from samples without 
C4AS and with C4AS are shown in Figure 2.6a and Figure 2.6b, respectively. We 
quantified the enrichment of droplets that were double positive using a Fisher's exact 
test, which readily distinguished samples with a C4AS gene from those without (Figure 
2.6c). In order to evaluate the accuracy of this ddPCR approach, we designed a long-
range PCR assay in which the forward primer was placed upstream of the HERV  
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Figure 2.6. Determining whether the AS form of the C4 gene is present in each genome. 
(a) A plot of fluorescence amplitudes from ddPCR for a sample without an AS gene, in 
which the two assays were C4A (FAM, y-axis) and C4S (VIC, x-axis). This sample 
shows no enrichment of double-positive droplets. (b) Plot of fluorescence amplitudes for 
a sample with an AS gene. Note the enrichment of double-positive droplets that contain 
templates with both C4A and C4S features. (c) P-values from a Fisher's exact test of 
non-independence of the number of droplets in each of the four quadrants. (d) 
Confirmation of the ddPCR-based results using a long-range PCR assay. The size of the 
expected product from a C4AS gene is ~5.1 kb and from a C4AL gene, ~11.5 kb. *, the 
same three samples identified using our ddPCR-based assay as containing a C4AS 
gene in (c). 
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sequence and the reverse primer was specific to the C4A sequence. This assay 
identified the same samples as containing C4AS as our ddPCR-based approach (Figure 
2.6d). We used these approaches to infer the diploid copy number of each C4 structural 
form in the HapMap CEU sample, and found that the number of AL genes varied from 0-
5 in a diploid genome; AS, 0-1; BL, 0-3; and BS, 0-3.  
  
The C4 locus exists in four common and several lower-frequency structural 
haplotypes 
In order to answer several questions about the population genetics of the C4 
locus, we needed to infer haplotype-specific copy number of C4 structural forms (and not 
just their diploid copy number as determined above): What is the structure of the C4 
locus on each human chromosome 6? What are the frequencies of C4 structural 
variants? What is their relationship to SNP haplotypes in the HLA locus? Can structural 
variation in C4 be made accessible to genotype imputation, using existing SNP genotype 
data?  
  
Haplotype-specific copy number of C4 structural forms can be inferred using genotypes, 
allele frequencies, and inheritance patterns  
Multiple combinations of alleles can give rise to the same diploid copy number for 
a multi-allelic CNV. For example, if a sample has 4 copies of the C4AL gene in a diploid 
genome, this could be a result of different allelic combinations: 0+4, 1+3, or 2+2. In order 
to distinguish between these possibilities, we made use of allele frequency information 
that is implicit in the diploid genotype data and additional constraints placed by 
inheritance in trios (Figure 2.7a). We used an expectation-maximization (EM) algorithm 
that incorporates this information, and we applied it to each C4 structural form (AL, AS,  
37 	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.7. Strategy for inferring haplotype-specific copy number of C4 structural forms. 
(a) Identifying transmitted and un-transmitted alleles using diploid copy number, 
estimation of allele frequencies, and inheritance patterns in father-mother-offspring trios. 
(b) An alternative approach that uses SNP backbone data to discriminate between 
multiple allelic combinations that can give rise to the same diploid copy number in each 
sample.  
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BL, and BS) separately. In this approach, we first enumerated the different allelic 
configurations that can give rise to each diploid copy number – in certain trios (e.g., a trio 
in which father, mother, and offspring had a copy number of 0, 2, and 1, respectively), 
only one configuration was possible under Mendelian inheritance, and in the rest of the 
trios, we made probabilistic inferences of haploid copy number. We used these 
inferences to estimate frequencies of each haploid allele, and then re-calculated the 
likelihood of each allelic combination in each trio given these allele frequency estimates. 
This allowed a new estimate of allele frequencies, which we then used to refine 
likelihoods of each allelic combination in each trio. We repeated this EM loop until the 
allele frequency estimates converged. Using this approach, we identified 4 alleles of AL 
copy number (0-3); 2 of AS copy number (0-1); 3 of BL copy number (0-2); and 3 of BS 
copy number (0-2). 
  
Haplotype-specific copy number can also be inferred by integrating diploid copy number 
data together with SNP genotype data 
The EM approach described above uses Mendelian transmission of copy number 
alleles in trios as a constraint in the inference of haploid copy number. If the C4 locus 
were highly mutable, it is possible for Mendelian inheritance to be violated and, in theory, 
not be detected when tracking inheritance in trios. We therefore developed an alternate 
approach to resolving haploid-copy number – one that does not assume Mendelian 
inheritance, but instead makes use of genotypes of SNPs surrounding the C4 locus. We 
reasoned that statistical relationships between SNPs and alleles of C4 could provide 
additional information that can be used to calculate the likelihood of observing each 
allelic combination given a diploid copy number (Figure 2.7b). In this approach, we 
assigned equal likelihoods to each genotype that could theoretically give rise to a copy 
number (e.g., 0+2 and 1+1 for a diploid copy number of 2). We then statistically phased 
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these probabilistic genotypes together with SNP genotypes, using Beagle113 (version 4), 
from which we obtained posterior genotype probabilities for each possible genotype. We 
applied this approach to the HapMap CEU sample (parents and offspring separately) 
and to each multi-allelic C4 structural form (AL, BL, and BS). In 98.7% (163/ 165) of the 
samples, the maximum posterior genotype probability was > 95%. We compared the 
results from this approach to those from the EM algorithm and found that the results 
were 97.2% concordant (the alleles inferred for 108/111 unrelated individuals using the 
two approaches were the same across the four structural forms).  
 
The C4 locus segregates in multiple structural haplotypes 
By tracking inheritance of each C4 structural form in trios, we were able to 
identify transmitted and un-transmitted alleles of each form. This allowed us to determine 
which alleles of C4 segregated together on the same chromosome and to define C4 
structural haplotypes. Although 72 haplotypes of C4 structural forms were theoretically 
possible (with 4 alleles of AL copy number, 2 of AS, 3 of BL, and 3 of BS), these 
structural forms segregated in only 15 haplotypes in the HapMap CEU sample (Figure 
2.8). Of these, four (AL-BL, AL-BS, AL-AL, and BS) were common (5%) and accounted 
for more than 90% of the haplotypes, and eleven lower-frequency haplotypes accounted 
for the rest.  
 
C4 copy number is partially correlated to individual SNPs in the HLA locus 
Having determined both diploid copy number as well as structural haplotypes of 
the C4 locus, we next evaluated the relationship between structural variation in C4 and 
surrounding SNPs in the HLA locus (genotypes of which were available through the 
HapMap Project). We calculated the correlation between the dosage of the minor allele  
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Figure 2.8. C4 structural haplotypes and their frequencies. Four common and eleven 
lower-frequency structural haplotypes of C4 were identified in the HapMap CEU sample 
of European ancestry. Counts and frequencies of the haplotypes are shown based on 
111 unrelated individuals (222 haplotypes). The order of the C4 genes within each 
haplotype is not meant to represent the physical position of the genes on the 
chromosome; instead, the schematic only represents the structural content of each 
haplotype. *, frequency not well established.  
 
of each SNP (from phase III of the HapMap Project) per diploid genome with copy 
number. Given the multi-allelic variation in C4, we expected the correlation with 
individual SNPs (with only two alleles) to be partial. Indeed, the maximum correlation of 
the genotype of any given HLA SNP to the copy number of C4A, C4B, C4L, and C4S 
was an r2 of 0.44, 0.33, 0.44, and 0.38, respectively (Figure 2.9), and no SNP more than 
200 kb away from the C4 locus had an r2 greater than 0.35 to the copy number of any 
C4 structural feature. These results are in contrast to the relationships among HLA 
SNPs as well as between HLA SNPs and classical alleles, which are stronger and 
extend over a longer range51. The partial correlation between individual HLA SNPs and 
copy number of C4 suggested that if C4 contributed to phenotypes, GWASs, which test 
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for association to single SNPs, may be underpowered to detect associations arising from 
copy number variation in this locus. This motivated an evaluation of whether structural 
variation in C4 relates more strongly to haplotypes of multiple SNPs.  
 
 
Figure 2.9. Correlation (r2) between genotypes of individual SNPs in the extended HLA 
locus and diploid copy number of (a) C4A, (b) C4B, (c) C4L, and (d), C4S in unrelated 
individuals from the HapMap CEU sample. Dashed, vertical blue lines indicate the 
position of the C4 locus.  
 
Common C4 structures segregate on multiple HLA haplotypes  
We assembled integrated haplotypes of HLA SNPs and C4 structures by jointly 
phasing C4 structural haplotypes with pre-phased haplotypes of HLA SNPs (from 25 Mb 
to 34 Mb on chromosome 6) from the HapMap Project. We thereby defined the HLA 
SNP haplotype(s) on which each C4 structure segregates. As expected, we found that  
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no individual SNP captured this complex form of structural variation. However, we 
observed a strong relationship between C4 structures and haplotypes of multiple SNPs, 
with a given C4 structure segregating on 1-5 common HLA haplotypes and a few less-
characteristic ones (Figure 2.10). The three most common C4 structures each 
segregated on 3-5 distinct SNP haplotypes, indicating that they may have arisen multiple 
times among human ancestors.  
We also related C4 structures to classical alleles of HLA-A, HLA-C, HLA-B, HLA-
DRB1, HLA-DQA1, and HLA-DQB1, using publicly available data for the classical HLA 
alleles114. The strongest relationship between any of the four common C4 structural 
haplotypes and an HLA classical allele was between the BS haplotype (which was long 
and uniform, Figure 2.10) and HLA-DRB1*03:01. 90% of the BS haplotypes contained 
an HLA-DRB1*03:01 allele and 69% of the HLA haplotypes with the HLA-DRB1*03:01 
allele also contained the C4 BS structure, with an r2 of 0.59. None of the other four 
common C4 structural haplotypes correlated to an HLA classical allele with an r2 of > 
0.3. 
  
C4 structural variation can be analyzed by imputation 
Based on the relationships between C4 structures and HLA SNP haplotypes, we 
hypothesized that it is possible to analyze C4 structural variation by imputation (Figure 
2.11).  We used the integrated haplotypes of HLA SNPs and C4 structures from 111 
unrelated individuals from the HapMap CEU sample that we created above as a 
reference panel for imputation. In order to evaluate the accuracy of inferences using this 
imputation approach, we performed a series of leave-one-out trials. In these trials, a 
different individual was removed from the reference panel in each trial, and the rest of 
the reference haplotypes were used to impute either copy number of C4 structural 
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Figure 2.10. HLA SNP haplotypes on which the four most common C4 structures 
segregate in the HapMap CEU sample. Each vertical line is a SNP, with gray indicating 
the major allele and black, the minor allele. The figure spans ~250 kb around the C4 
locus. Note that the three most common C4 structures each segregate on multiple HLA 
SNP haplotypes – AL-BS on 5 distinct haplotypes and 1 poorly-defined set of ("other") 
haplotypes; AL-BL on 3 well-defined and 1 other set of haplotypes and AL-AL on 2 
haplotypes. Each set of haplotypes shown in this figure is present at a frequency of at 
least 3.5% (at least 8 occurrences) in the CEU population sample.  
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features or C4 structures based on the test individual's genotypes for different sets of 
SNPs: HapMap Phase III, Illumina Immunochip, Illumina OmniExpress, and Affymetrix 
6.0. We calculated the correlation (r2) between the probabilistic dosage from imputation 
(using Beagle115) and the experimentally-determined genotypes.  
  
 
 
 
 
 
 
 
Figure 2.11. Simplified schematic of imputation of C4 structures from SNP genotype 
data. A panel of reference haplotypes constructed by jointly phasing C4 structures with 
HLA SNP haplotypes was used to impute C4 structural variation from surrounding SNP 
genotype data in individuals (e.g., such as those in a GWAS) for whom SNP genotypes 
(but not C4 structure) is known.  
 
Through these leave-one-out trials, we found that C4 structures and copy 
number can be imputed from SNP haplotypes imperfectly, but with greater accuracy 
than was possible using the best individual tag SNP that we identified (Figure 2.12). The 
prediction from imputation correlated with the copy number measurements from ddPCR 
more strongly for copy number of C4L, C4S, and C4A (r2 of 0.80-0.85, 0.68-0.80, and 
0.6-0.75, respectively) than for copy number of C4B (r2 of 0.36-0.45). Imputation was 
also able to predict genotypes of the four common C4 structures – with greater accuracy 
for BS and AL-BS (r2 of 0.75-0.92 and 0.81-0.84, respectively) than for AL-BL and AL-AL 
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Figure 2.12. Imputability of C4 structural variation, as estimated from a series of leave-
one-out trials within our reference panel. (a) r2 from Pearson correlation between the 
copy number of each structural feature, as determined by ddPCR, and the genotype of a 
single SNP that we identified as correlating most strongly with copy number (gray) or 
imputation-based probabilistic dosages (colored bars) using different sets of SNPs as 
indicated in the legend. (b) r2 between the dosage per diploid genome (0, 1, or 2) of each 
of the four common C4 structures that we identified using our approach described 
earlier, and the genotype of the best tag SNP we identified or the dosage from 
imputation. Error bars represent 95% confidence intervals around the Pearson r2 value.  
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Figure 2.12 (continued) 
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 (r2 of 0.56-0.68 and 0.50-0.59, respectively). The accuracy of imputation using sets of 
HLA SNPs on different genotyping array platforms was comparable.  
 
Discussion  
We have described a novel combination of molecular and statistical approaches 
for characterizing complex genome structural variation and have applied it to the C4 
locus. The extension of this approach to other loci in the human genome that are 
structurally complex will provide a better understanding of how such loci vary across 
individuals and populations and reveal their relationship to single nucleotide variation.   
The high level of concordance between our ddPCR approach and orthogonal 
molecular and computational approaches provides confidence in our copy number 
measurements of the C4 locus. Although these measurements of diploid copy number 
revealed a high degree of polymorphism of the individual structural features of C4, our 
analysis of C4 structure on a per-chromosome level indicated that four common 
haplotypes of C4 structure were sufficient to account for much of this apparent structural 
complexity in the locus.   
Prior studies of the C4 locus109, 110, 116 have also described the extent of copy 
number variation in C4 and revealed its various structural forms. Based on evaluating 
the relationship of structural variation in C4 to a limited number of SNPs in the HLA 
locus, these studies concluded that SNP genotypes cannot serve as proxies for C4 copy 
number110 nor can C4 structural variation be used for prediction of HLA haplotypes116. 
Our work is the first to critically evaluate the extent to which C4 structural variation can 
be captured through imputation. The results from our leave-one-out analyses suggested 
that C4 structural variation can be predicted from SNP genotypes using imputation, with 
multiple features of C4 variation predicted with strong correlation (r2 > 0.7) between 
imputed and experimentally-derived genotypes. Although imputation did not capture the 
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full extent of structural variation in C4, our approach is enabling in powerful ways. First, it 
allows inexpensive and immediate investigation of the contribution of C4 structural 
variation to phenotypes, making use of already existing, vast SNP genotype data from 
GWASs. The power lost as a result of imperfectly predicting genotypes through 
imputation is offset by the ability gained to evaluate association to phenotypes in 
exceedingly large GWAS data sets. This ability to conduct well-powered studies is 
critical for complex phenotypes like SLE and schizophrenia in which the effect that 
individual loci have on the phenotype is relatively small. Furthermore, because ddPCR is 
highly scalable (i.e., compared to other approaches for analyzing the C4 locus, such as 
Southern blot analysis or whole-genome sequencing), we can critically evaluate 
association results from imputation by direct molecular analysis in large, clinical cohorts. 
Finally, the ability to relate phenotypes to a series of specific structures of C4 (even if 
they are not determined with full confidence) enables testing association to phenotypes 
in novel and powerful ways, which we will demonstrate in Chapters 3 and 4.  
  
Contributions 
The strategy presented in this chapter for characterizing complex structural 
variation was developed with Steve McCarroll's guidance and input. Robert Handsaker 
performed read-depth analysis of whole-genome sequence data to calculate C4 copy 
number using Genome STRiP.  
  
Methods 
Determining copy number of C4 CNVs using qPCR 
The qPCR assays and reaction conditions for typing the C4 CNVs were based on 
Wu et al109. The oligonucleotide sequences for the primers and probes are listed in 
Supplemental Table 1. The reverse primer of the assays used for typing C4A and C4B 
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copy number were designed to the paraolog-defining sequence on exon 26. The 
reactions were performed in 10 µl, with 15 ng of input genomic DNA, 2x TaqMan 
universal PCR master mix (Applied Biosystems), forward and reverse primers each at a 
final concentration 500 nM, VIC-labeled TaqMan MGB probe for C4 and a FAM-labeled 
TaqMan MGB probe for RP1 (reference locus), each at a final concentration of 100 nM. 
PCR was performed on a CFX384 Real-Time PCR Detection System (Bio-Rad 
Laboratories) with the following cycling conditions: 95°C for 10 minutes, followed by 40 
cycles of 95°C for 15 seconds and 60°C (for C4A) or 59°C (for C4B) for 1 minute. 
  
Determining copy number of C4 CNVs using ddPCR  
50 ng of genomic DNA was digested in 10 µl, using 1 unit of AluI (New England 
Biolabs) at 37°C for 1 hour. The digested DNA was diluted two-fold with water. The 
oligonucleotide sequences for the primers and probes for assaying copy number of C4A, 
C4B, C4L, and C4S were from Wu et al.109  and are listed in Supplemental Table 1.  
Reaction mixtures consisted of 6.25 µl of the digested, diluted DNA, 1 µl of 20x primer-
probe mix (containing 18 µM of forward and reverse primers each and 5 µM of 
fluorescent probe) for C4 and a reference locus (RPP30) each, and 2x ddPCR Supermix 
for Probes (Bio-Rad Laboratories). For each sample, this reaction mixture was each 
emulsified into approximately 20,000 droplets in an oil/aqueous emulsion, using a 
microfluidic droplet generator (Bio-Rad Laboratories). PCR was performed within the 
droplets using the following cycling conditions: 95°C for 10 minutes, 40 cycles of 94°C 
for 30 seconds and 60°C (for C4A and C4L) or 59°C (for C4B and C4S) for 1 minute, 
followed by 98°C for 10 minutes. After PCR, the fluorescence from each of the two 
fluorophores in each droplet was read by a QX100 droplet reader (Bio-Rad 
Laboratories). Data were analyzed using the QuantaSoft software (Bio-Rad 
Laboratories), which estimates absolute concentration of DNA templates by Poisson-
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correcting the fraction of droplets that are positive for each amplicon (C4 or RPP30). The 
ratio of the concentration of the C4 amplicon to that of the reference (RPP30) amplicon 
multiplied by two (the number of copies of the reference locus in a diploid genome) 
yields the absolute number of copies of the C4 CNV in a diploid genome.  
  
Detecting the presence of the C4AS structural form using ddPCR  
A long-range PCR was first performed to enrich for DNA templates that spanned 
the L/S and A/B-defining molecular features (in intron 9 and exon 26, respectively). The 
oligonucleotide sequences for this long-range PCR assay are provided in Supplemental 
Table 1. The reaction was performed in 50 µl and consisted of 50 ng of input genomic 
DNA, 5X Long Range Buffer (Mg2+ free) (Kapa Biosystems), 25 mM MgCl2, 10 mM of 
each dNTPs and 10 uM each of forward and reverse primers and 12.5 units of Kapa 
LongRange DNA Polymerase. Cycling conditions were as follows: 94°C for 2 minutes; 
35 cycles of 94°C for 25 seconds, 61.4°C for 15 seconds, and 68°C for 11 minutes; and 
72°C for 11 minutes.  
The PCR product from the long-range PCR was used as input into the ddPCR 
assay. In order to add an appropriate amount of DNA into the ddPCR assay, the long-
range PCR products were quantified using a Qubit Fluorometer (Life Technologies). 
Based on the quantification, PCR products were diluted to contain approximately 4,000 
copies per µl and 8 µl of this diluted DNA was added to a ddPCR mixture containing 1 µl 
of a 20x primer-probe mixture of the C4A assay (FAM), 1 µl of a 20x primer-probe 
mixture of the C4S assay (VIC), and 10 µl of 2x ddPCR Supermix for Probes (Bio-Rad 
Laboratories). The generation of droplets and the PCR cycling conditions were as 
described above for the ddPCR assays of C4 copy number, with an annealing 
temperature of 59°C. After droplets were read, a Fisher's exact test was performed to 
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test independence of the number of droplets falling into each of the four possible 
classes: (i) FAM-VIC-, (ii) FAM-VIC+, (iii) FAM+VIC-, and (iv) FAM+VIC+.  
  
Detecting the presence of the C4AS structural form using long-range PCR  
In order to evaluate the accuracy of the results from the ddPCR-based approach 
for detecting the presence of the AS form of the C4 gene, we designed a second long-
range PCR assay. In this assay, we used a forward primer upstream of the HERV 
sequence and the reverse primer against the sequence specific to C4A in exon 26 
(sequences in Supplemental Table 1), in order to amplify both AS and AL genes, and 
distinguish them based on the size of the product (~5.1 kb from a C4AS gene and ~11.5 
kb from a C4AL gene). Reaction mixtures and cycling conditions were as described for 
the long-range PCR above, with an annealing temperature of 59°C.  
  
Inferring phase of haploid-specific copy number alleles in ambiguous trios  
In some trios, it was not possible to unambiguously identify which alleles were 
transmitted and un-transmitted using our EM algorithm. For example, if all three 
individuals in a trio had a copy number of 1, each parent could have transmitted either 
the 0- or the 1-copy allele to the offspring. In order to resolve these ambiguities, we 
made use of the SNP backbone data available for these individuals from the HapMap 
project. We created a reference set of haplotypes containing both SNPs and copy 
number alleles from trios in which haploid-specific copy number and the transmission 
status of each allele were inferred confidently. We then used this core set of haplotypes 
as a reference to phase the copy number alleles onto SNP haplotypes using Beagle113 
for trios in which transmission status of the copy number alleles was ambiguous.  
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Inferring haploid-specific copy number using diploid genotypes of copy number and SNP 
genotypes  
We used genotypes of SNPs within ~1 Mb on either side of the C4 locus (from 31 
Mb to 33 Mb on chromosome 6) in order to distinguish between the multiple allelic 
combinations that could theoretically give rise to each diploid copy number. For each 
given diploid copy number, we provided a vector of genotype likelihoods as input for 
phasing in Beagle117 (version 4). For example, for an individual with a diploid copy 
number of 4, two allelic combinations are possible – 2+2 and 1+3 – if the alleles 
segregating in the population were 0, 1, 2, and 3. In the corresponding vector of 
likelihoods, these two genotypes were encoded as equally likely (log10 likelihood of -0.3), 
and the remaining eight genotypes that do not give rise to a diploid copy number of 4 
were assigned a log10 likelihood of -1000 (i.e., to indicate that they are extremely 
unlikely). We phased these likelihoods together with SNP genotypes and obtained 
posterior genotype probabilities for each possible genotype, for each individual. These 
probability estimates readily identified the most likely genotype for each individual (the 
maximum posterior genotype probability was > 95% for ~99% of the samples).  
  
Imputation of C4 structural variants using Beagle115 
In order to use existing imputation algorithms (which are well-equipped to handle 
biallelic variants such as SNPs) for analysis of multi-allelic variants, we encoded 
structural variants in C4 as a series of pseudo-biallelic variants. For C4 CNVs, we 
created n-1 pseudo-biallelic variants for a variant with n alleles and encoded them such 
that the sum of the alleles across these variants would equal the copy number, as 
illustrated below (Figure 2.13): 
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Figure 2.13. Encoding C4 copy number variants (CNVs) as a series of pseudo-biallelic 
variants. For a C4 CNV with n alleles, n-1 biallelic variants were created such that the 
sum of the alleles across these variants would equal the copy number.  
 
For C4 structures, we created a pseudo-biallelic variant for each of the 15 structures. If a 
haplotype contained a given C4 structure, the corresponding variant would be encoded 
with a '1' allele and, if absent, a '0' allele.  
This encoding scheme allowed Beagle to yield probabilistic dosages from 
imputation for each variant. For imputation of C4 CNVs, we summed these dosages 
across the constituent pseudo-biallelic variants to obtain the imputed estimate of copy 
number. For imputation of C4 structures, we used the imputed dosage from the 
corresponding pseudo-biallelic variant directly as an estimate of the dosage of that given 
structure in a diploid genome. We then evaluated correlation between these imputed 
dosages and experimentally derived genotypes to calculate an r2 value as a metric of 
imputation accuracy.  
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Introduction  
The association of genetic variation in the HLA locus to systemic lupus 
erythematosus (SLE) is strong, complex, and unsolved, as described in Chapter 1. The 
C4 gene, within the HLA locus, has been investigated in SLE since 1974118, but the 
question of whether structural variation in C4 contributes to the HLA association signal in 
SLE is unsettled due to various limitations of these studies. Early studies of C4 in SLE119, 
120 profiled C4 protein levels in the serum and used this as a marker of genetic variation 
in the C4 locus. However, such studies were confounded by the fact C4 and other 
complement components are consumed during the course of active disease in SLE. 
Other studies have investigated copy number variation at the C4 locus and have 
reported association to low copy number58, 59 but without accounting for variation in the 
HLA locus outside of C4. As a result, it is unclear whether the apparent association of 
C4 to SLE is due to linkage disequilibrium (LD) with variation in HLA classical genes. A 
more recent study investigated copy number variation in C4 in the context of variation 
elsewhere in the HLA locus and concluded that C4 CNVs are not an independent risk 
factor for SLE60. However, this report did not examine the full range of copy number 
variation in C4, nor did it investigate association to the length polymorphism in C4.  
Having characterized structural variation in C4 and its relationship to surrounding 
variation in the HLA locus, we sought to apply the methods developed in Chapter 2 
toward evaluating the role of the C4 locus in SLE. We hypothesized that structural 
variation in C4 contributes to SLE (and to the HLA association signal) based on the 
following lines of reasoning. First, complete deficiency of C4, though rare, is one of the 
strongest risk factors for SLE57, 121, and we reasoned that common forms of copy number 
variation in the C4 locus could also contribute to SLE. Second, other genes that function 
in the complement pathway have also been implicated in SLE. Complete deficiencies of 
C1q, which functions upstream of C4 in the complement pathway also contribute to 
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SLE122, 123. In addition, common variants in the ITGAM locus, which encodes a receptor 
for iC3b (a proteolytic cleavage fragment of the central protein of the complement 
pathway), have been found to associate to SLE from genome-wide association studies44, 
46. Third, studies of C4 knockout mice support a role for C4 in SLE124 – whereas 
association studies of the C4 locus in humans are complicated by LD to HLA classical 
alleles, the presence of a lupus-like phenotype in C4-deficient mice raises the suspicion 
that C4 may independently contribute to SLE pathogenesis. Fourth, a role for C4 in SLE 
is biologically plausible and is consistent with the current understanding of SLE 
pathogenesis. Complement proteins may play a role in clearance of apoptotic cells125, 
and patients with SLE have defective clearance of apoptotic debris126, which can act as 
a source of auto-antigens127 and contribute to inflammation128.  
  
C4A gene expression in lymphoblastoid cell lines is directly proportional to C4A 
gene copy number 
We evaluated the relationship between C4 structural variation and C4A 
expression in 46 lymphoblastoid cell lines from HapMap CEU and YRI samples. We 
measured gene expression using reverse-transcriptase droplet digital PCR (RT-ddPCR). 
Analogous to the ddPCR approach described in Chapter 2, RT-ddPCR involves a 
reverse-transcription step that occurs within the droplets prior to PCR amplification. 
Primers and fluorescent probes against the target locus of interest (C4) as well as a 
control locus are included in the RT-ddPCR assay, and absolute quantification of the 
number of RNA templates from each locus is obtained. By normalizing the concentration 
of C4 RNA to the RNA from a control locus, variation in the amount of input RNA is 
accounted for, allowing for comparison of gene expression levels across samples.  
Across 46 unrelated samples (23 from CEU and 23 from YRI), C4A copy number 
associated with C4A expression (p = 1.5x10-9), with expression levels directly 
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proportional to gene dosage (Figure 3.1a). The association was driven primarily by the 
CEU samples (p = 3.0x10-7), which showed greater variation in C4A copy number than 
YRI samples (0-4 compared to 2-3). C4A gene copy number explained 62% of the 
variance in C4A expression and the intercept from a linear model fitting C4A expression 
to C4A copy number was not statistically different from 0 (p = 0.39).   
We then related C4A expression in LCLs to the four common C4 structures in 
CEU samples. We calculated an effect size, β, associated with each of the four 
structures from fitting C4A expression to the number of chromosomes per diploid 
genome that carried that structure (0, 1, or 2). These four common C4 structures 
associated to C4A expression levels in proportion to the number of C4A genes they 
contained (Figure 3.1b).  
 
HLA-DRB1 alleles and C4A copy number are strongly associated to SLE  
We tested for association between C4 structural variation and SLE risk in 2,390 
SLE cases and 8,707 controls of European ancestry drawn from several cohorts 
sampled within the US129-131. These samples were genotyped on the Immunochip 
(Illumina), a SNP microarray that contains approximately 200,000 SNPs enriched for 
variants associated to immune-mediated diseases, with dense coverage of the HLA 
locus. We used genotypes from the Immunochip for these samples as the SNP 
backbone for imputation of C4 structural variation, using the reference panel and 
imputation approach described in Chapter 2. In addition, we also imputed HLA classical 
alleles, both using a reference panel enables joint imputation of C4 structural variants 
and classical alleles as well as a much larger reference panel for imputation of classical 
alleles and HLA SNPs114.  
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Figure 3.1 Association of C4 structural variation to C4A expression in lymphoblastoid 
cell lines. (a) C4A expression was directly proportional to C4A gene copy number. (b) 
The four common structures of C4 associated to C4A expression in proportion to the 
number of C4A copies (orange rectangles) they contain. β measures the effect size 
calculated from a linear model fitting C4A expression to the number of chromosomes (0, 
1, or 2) carrying that C4 structure per diploid genome.  
 
Association analysis of HLA SNPs, HLA classical alleles, and copy number of C4 
structural features, revealed a strong association of the HLA locus to SLE risk (Figure 
3.2). The variant most strongly associated to SLE was rs1059615 (p = 2.3x10-41), a 
synonymous variant in HLA-DRB1. rs1059615 was strongly correlated with HLA-
DRB1*03:01 (r2 = 0.98), which was also among the most strongly associated variants (p 
= 6.2x10-41). Given that HLA-DRB1*03:01 is a previously well-replicated variant in SLE 
and it was in near-perfect linkage disequilibrium with rs1059615, we investigated HLA-
DRB1*03:01 in subsequent analyses as the primary signal from the Class II region of the 
HLA locus. HLA-DRB1*15:01, another HLA-DRB1 allele that has been consistently 
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implicated in SLE, showed weaker association (p = 6.2x10-5). However, in a joint 
regression model with HLA-DRB1*03:01 and HLA-DRB1*15:01, the association to both 
variants strengthened (p = 3.2x10-46 for HLA-DRB1*03:01; p = 1.54x10-10 for HLA-
DRB1*15:01). Both alleles associated to SLE risk with a dominant effect (Figure 3.3), 
and we accordingly modeled a dominant effect of these HLA-DRB1 alleles in 
subsequent association analyses.  
 
 
Figure 3.2. Association of the HLA locus to SLE. Directly genotyped variants as well as 
imputed variants (C4 structural variants and HLA classical alleles) were evaluated for 
association to SLE.  
 
Copy number of C4A associated more strongly to SLE than other structural 
features of C4 (p = 1.8x10-37; Figure 3.2). Despite an estimated r2 of 0.65 (0.55 - 0.75) 
between imputed and experimentally-derived genotypes of C4A copy number (based on 
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leave-one-out trials described in Chapter 2, Figure 2.12), the strength of association was 
comparable to the most strongly associated variants in the HLA locus. In joint models of 
association to SLE, copy number of no other C4 structural feature explained the 
association to C4A copy number (Table 3.1).  
 
 
 
 
 
 
 
 
 
 
Figure 3.3. HLA-DRB1 alleles, (a) *03:01 and (b) *15:01, associated to SLE risk with a 
dominant effect.  
 
 
Increased copy number of C4A is associated with lower risk of SLE independently 
of HLA-DRB1 risk alleles 
The above analyses identified a strong association of SLE to C4A copy number 
as well as to HLA-DRB1 risk alleles, and we next sought to evaluate the independence 
of these effects. C4A copy number was partially correlated with HLA-DRB1*03:01 (r2 = 
0.45) but not with *15:01 (r2 = 0.005). In a joint model with these variants, C4A copy 
number remained associated to SLE (p = 9.1x10-7, Table 3.2).  
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Table 3.1. Association of C4 CNVs to SLE. P-values for imputed copy number of C4 
structural features are shown before and after conditioning on the indicated variant.   
 
Conditional on: 
- 
C4A 
copy 
number 
C4B copy 
number 
C4L copy 
number 
C4S copy 
number 
C4 (total) 
copy 
number 
C4A copy 
number 1.8x10
-37 - 1.8x10-32 1.6x10-11 6.4x10-27 6.4x10-6 
C4B copy 
number 1.2x10
-8 0.02 - 4.3x10-3 2.2x10-4 6.4x10-6 
C4L copy 
number 2.5x10
-28 0.16 2.5x10-22 - 5.3x10-25 0.04 
C4S copy 
number 4.9x10
-12 0.67 2.1x10-7 1.2x10-8 - 0.04 
C4 (total) copy 
number 1.1x10
-35 0.02 1.8x10-32 1.2x10-8 5.3x10-25 - 
 
 
Table 3.2. Association of SLE to imputed C4A copy number, HLA-DRB1*03:01 and 
*15:01 from a joint model. The p-values for the DRB1 risk variants are from modeling a 
dominant effect on SLE risk.  
 
Conditional on: 
- 
HLA-
DRB1*03:01 
and *15:01 
HLA-
DRB1*15:01 
and C4A copy 
number 
HLA-
DRB1*03:01 
and C4A copy 
number 
C4A copy 
number 1.8x10
-37 9.1x10-7 - - 
HLA-
DRB1*03:01 6.4x10
-42 - 6.5x10-12 - 
HLA-
DRB1*15:01 3.2x10
-5 - - 6.5x10-10 
 
We then evaluated the risk associated with imputed copy number of C4A per 
diploid genome and the extent to which this was influenced by DRB1 risk variants. Prior 
to conditioning on *03:01 and *15:01, lower copy number of C4A (0 or 1) was associated 
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with higher risk of SLE, and higher copy number (2 or 3) was associated with lower risk, 
but the effect of copy number on risk was not linear (Figure 3.4a). After including *03:01 
in the model together with C4A copy number, the risk associated with a diploid copy 
number of 0 or 1 was moderated (Figure 3.4b). Including *15:01 in the model with C4A 
copy number had little-to-no effect on the risk associated with C4A copy number (Figure 
3.4c), consistent with the lack of correlation in the genotypes of these variants. The 
pattern of association to imputed copy number of C4A after including both *03:01 
and*15:01 in the model was consistent with a linear, dose-dependent relationship, in 
which increasing copy number of C4A associated with lower risk of SLE (Figure 3.4d). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4. Association of SLE to (imputed) C4A copy number. (a) Odds ratio 
associated with the four most common diploid copy numbers is shown prior to 
conditioning on HLA-DRB1 risk variants, (b) conditional on HLA-DRB1*03:01, (c) 
conditional on HLA-DRB1*15:01, and (d) conditional on both HLA-DRB1*03:01 and 
HLA-DRB1*15:01.  
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In order to better understand the relationship of C4 to SLE risk, we next 
evaluated the association of SLE to the four most common C4 structures (AL-BL, AL-BS, 
AL-AL and BS) – the substrates underlying the variation in copy number of C4. These 
structures associated to SLE with three independent levels of risk, spanning a wide 
range of odds ratios – AL-AL (two copies of C4A), with a lower level of risk (OR = 0.65, 
95% CI: 0.57-0.75); AL-BL and AL-BS, (one copy of C4A each), with intermediate, 
similar levels of risk (OR = 0.96, 95% CI:  0.91-1.02; OR = 0.90, 95% CI: 0.83-0.97, 
respectively); and BS, (no copies of C4A), with a higher level of risk (OR = 1.79, 95% CI: 
1.64-1.96) (Figure 3.5a). The effect size associated with BS appeared to be higher than 
expected based on the association of SLE to the other three C4 structures. Consistent 
with the finding in Chapter 2 that 90% of BS haplotypes also contained an HLA-
DRB1*03:01 allele, the effect size associated with BS was moderated when including 
*03:01 in the model with C4 (Figure 3.5b). Including *15:01 in the model had a minimal 
effect on the association of C4 structures to SLE risk (Figure 3.5c), and including both 
*03:01 and *15:01 in the model with C4 rationalized the pattern of association of C4 
structures to SLE risk (Figure 3.5d) – the effect size associated with each C4 structure 
was inversely proportional to the number of copies of C4A the structure contains. In 
addition, the association of C4 structures to SLE risk mirrored the pattern of association 
of the same structures to expression of C4A in lymphoblastoid cell lines (Figure 3.1b).  
The association of C4 structures to SLE with three distinct levels of risk 
suggested that this result was unlikely to be due to correlation of C4 structural variation 
with a single, bi-allelic variant or SNP. However, in theory, functional variant(s) outside of 
the C4 locus could load onto haplotypes of different C4 structures with varying 
frequencies such that C4 structures segregating on haplotypes with a larger fraction of 
such risk variants could appear to associate with higher levels of risk. In addition, 
variants other than the HLA-DRB1 risk alleles that we did not explicitly model in a 
64 	  
conditional regression analysis could be influencing association to C4. We therefore 
developed a form of association testing that exploited the population genetic properties 
of the C4 locus to evaluate the extent to which the HLA haplotypes each C4 structure 
segregates on influenced its association to SLE.  
 
 
Figure 3.5. Association of SLE to the four most common C4 structures. (a) Odds ratio 
associated with each C4 structure is shown prior to conditioning on HLA-DRB1 risk 
variants, (b) conditional on HLA-DRB1*03:01, (c) conditional on HLA-DRB1*15:01, and 
(d) conditional on both HLA-DRB1*03:01 and HLA-DRB1*15:01. Note that the 
association of C4 structures to SLE risk mirrors their association to C4A expression in 
lymphoblastoid cell lines (Figure 3.1b). Note also that the outsized effect associated with 
the BS structure in (a) was moderated upon including *03:01 in the model (b and d).  
 
Recurrence of C4 structures on different HLA haplotypes enables a novel form of 
association analysis  
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In Chapter 2, we found that the three most common C4 structures each 
segregated on multiple HLA haplotype backgrounds (Figure 2.10). In order to distinguish 
between the effect of C4 structural variation and effects elsewhere in the HLA locus, we 
exploited the fact that the same C4 structures existed on different HLA haplotype 
backgrounds. We treated C4 structures segregating on different haplotypes as separate 
alleles. The presence of this long allelic series (of 11 alleles, each at a frequency of 
more than 3%) enabled a novel form of association testing, in which the occurrence of a 
C4 structure on each new HLA haplotype yielded an additional falsifiable test of its 
association to SLE. If C4 structural variation had a causal influence on SLE risk, then the 
same C4 structure should show similar levels of association to SLE, regardless of which 
haplotype it segregated on.  
In order to test this prediction, we encoded C4 structures as separate alleles if 
they segregated on different HLA haplotype backgrounds in our reference panel for 
imputation. We then imputed these C4 structural alleles into the SLE case-control 
samples, using the surrounding SNP genotype data as the backbone for imputation, and 
evaluated association to each of these alleles. The ranking of effect sizes associated 
with each C4 allele was consistent with the number of copies of C4A each allele 
contained (Figure 3.6a) – the BS allele, with no copies of C4A, was associated with a 
higher risk than any of the 8 alleles with 1 copy of C4A, which in turn were associated 
with a higher risk than the 2 alleles with 2 copies of C4A (Figure 3.6a). The correlation 
of effect sizes across these 11 alleles with their C4A copy number was statistically 
significant (p = 7.8x10-4, Pearson correlation). This overall pattern of association to the 
11 C4 alleles was preserved in joint models that included HLA-DRB1*03:01 (Figure 
3.6b), HLA-DRB1*15:01 (Figure 3.6c), or both (Figure 3.6d), together with C4 alleles, 
with a moderation of effect size associated with BS in models that included *03:01.  
 
66 	  
 
Figure 3.6. Association of SLE to C4 structures segregating on different HLA haplotypes 
backgrounds. (a) Odds ratio associated with each C4 allele is shown prior to 
conditioning on HLA-DRB1 risk variants, (b) conditional on HLA-DRB1*03:01, (c) 
conditional on HLA-DRB1*15:01, and (d) conditional on both HLA-DRB1*03:01 and 
HLA-DRB1*15:01. C4 structures suffixed with a different number (e.g., AL-BL 1 and AL-
BL 2) represent alleles with the same structural content but segregating on different HLA 
haplotype backgrounds, and they correspond to the annotation in Figure 2.10 in Chapter 
2. The diamond symbols in bolder colors represent the effect size from a meta-analysis 
across alleles that have the same C4 structural content.  
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SLE associates more strongly to C4A copy number measured using ddPCR than 
to imputed copy number 
The analyses described above represent the first attempts to use imputation to 
assess contribution of complex structural variation to a phenotype. Therefore, we sought 
to evaluate the accuracy of this approach using direct molecular measurements from 
droplet-digital PCR (ddPCR, described in Chapter 2). We used ddPCR to measure C4A 
copy number in 698 cases and 1,226 controls available from the larger set of samples 
analyzed using imputation. As expected, C4A copy number, determined by ddPCR, 
associated more strongly to SLE (p = 3.9x10-6) than imputed C4A copy number (p = 
6.1x10-4) for the same samples. In principle, this improvement in the strength of 
association could be a result of the ddPCR-based genotypes correlating more strongly, 
than imputation-based C4A copy number, with HLA-DRB1 risk variants. However, the 
correlation was approximately the same based on ddPCR (r2 = 0.30 to *03:01; 0.0 to 
*15:01) and imputation (r2 = 0.35 to *03:01; 0.0 to *15:01) across these 1,924 samples.  
 
Discussion 
We have investigated the contribution of structural variation in C4 to SLE and 
have found that its association to SLE was not fully explained by previously identified 
risk alleles, HLA-DRB1*03:01 and *15:01, and that it is unlikely to be a result of 
correlation with variation elsewhere in the HLA locus. To our knowledge, this is the first 
study to investigate the contribution of complex structural variation to a phenotype using 
imputation, and more specifically, of the full extent of structural variation in C4 (including 
copy number of each structural feature – C4A, C4B, C4L, and C4S) to SLE.  
Our finding that SLE associates to C4 independently of HLA-DRB1 risk alleles 
disagrees with that of Boteva et al.60, who concluded that C4 copy number is not an 
independent risk factor for SLE. This discrepancy can be reconciled based on the 
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following differences between our studies. First, the sample size in Boteva et al. was 501 
SLE cases and 719 controls (and an additional 464 cases and 449 controls from a 
second, independent cohort), whereas we analyzed a much larger set of samples (2,390 
cases and 8,707 controls). Our effective sample size is reduced, however, because of 
imperfectly predicting genotypes using imputation. The sample size required to achieve 
the same level of statistical power is increased by a factor of 1/r2, where r2 is the 
squared-correlation between the genotypes tested for association and the genotypes of 
the causal variant132. Based on this relationship and our estimates of imputation 
accuracy from Chapter 2 (Figure 2.12), our effective sample size is reduced by a factor 
of 1.3 - 1.8 (but still larger than that of Boteva et al). Second, in testing association to C4 
copy number, Boteva et al. grouped C4A copy numbers into high- and low-copy number 
classes in reference to a copy number of 2. Under a model of a linear, dose-dependent 
effect of C4A copy number on SLE risk, this approach reduces statistical power. Third, in 
testing conditional association, they restricted their analyses to only samples with a copy 
number of 0, 1, or 2 – the resulting reduction in sample size (and variance in the 
genotype) decreased their statistical power. Furthermore, restricting analysis to three 
copy number genotypes (0, 1, and 2) that can, in principle, be readily tagged by SNPs 
and classical alleles that are bi-allelic, could also result in a stronger correlation between 
the genotypes of these variants and a reduction in the strength of association from a 
conditional regression analysis.  
Our ddPCR-based analysis of a subset of the SLE case-control samples that 
were analyzed by imputation revealed a stronger association of SLE to C4A copy 
number ascertained from a molecular assay, compared to the statistical prediction from 
imputation. Considering that imputed copy number of C4A was already among the most 
strongly associated variants in the HLA locus, it is possible for more accurate 
measurements of copy number (i.e., from ddPCR) on the entire cohort of samples to 
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result in a stronger association of C4A copy number to SLE than any other variant in the 
HLA locus. In addition, our results offer a potential explanation for the observation that 
the HLA locus appears to have an outsized association signal compared to other loci 
that have been identified from genome-wide association studies of SLE (Chapter 1, 
Figure 1.1a) – the risk allele of HLA-DRB1*03:01 and C4 BS are mostly present on the 
same, long haplotype, contributing to the strength of each other's association to SLE.  
Our finding of a considerably stronger association of SLE to C4A copy number 
than to C4B copy number suggests a functional difference between these two paralogs 
(which are > 99% identical at the nucleotide level). This finding may reflect the 
differences in the biochemical properties of these two paralogs that have been described 
previously108. In particular, the higher affinity of C4A for amino groups (such as those in 
immune complexes) than C4B, which binds more strongly to hydroxyl groups (such as 
those in carbohydrate moieties on bacterial antigens), may underlie the differences in 
their contribution to SLE risk. Furthermore, the association of the structures that are 
protective in SLE with higher expression of C4A is consistent with the current 
understanding of the pathogenesis of the disease, in which complement is hypothesized 
to play a protective role by participating in clearance of apoptotic debris101 and 
maintenance of self-tolerance103.  
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(Hofstra North Shore-LIJ School of Medicine). Vanessa Van Doren performed the 
ddPCR assays to type C4A copy number in these samples.  
 
Methods 
Analysis of gene expression in lymphoblastoid cell lines (LCLs) 
 We used RT-ddPCR assays to measure expression of C4 in lymphoblastoid cell 
lines (LCLs). We designed the primers so that amplicons would span across splice 
junctions in order to minimize the detection of residual genomic DNA in the assay 
(sequences provided in Supplemental Table 1). Reactions were performed in 20 µl with 
35 ng of total RNA as input, 10 µl of 2x one-step RT-ddPCR mix (Bio-Rad laboratories), 
0.8 µl of 25 mM manganese acetate, and 1 µl of 20x primer-probe mix (containing 18 µM 
of forward and reverse primers each and 5 µM of fluorescent probe) for C4 and a control 
locus (NUDCD3, NudC domain containing 3) each. For each sample, this reaction 
mixture was emulsified into approximately 20,000 droplets in an oil/aqueous emulsion, 
using a microfluidic droplet generator (Bio-Rad Laboratories). RT-ddPCR was performed 
within the droplets using the following cycling conditions: 60°C for 30 minutes, 95°C for 5 
minutes, 40 cycles of 94°C for 30 seconds and 60°C for 1 minute, followed by 98°C for 
10 minutes. After PCR, the fluorescence from each of the two fluorophores in each 
droplet was read by a QX100 droplet reader (Bio-Rad Laboratories). Data were analyzed 
using the QuantaSoft software (Bio-Rad Laboratories), which estimates absolute 
concentration of templates by Poisson-correcting the fraction of droplets that are positive 
for each amplicon (C4 or NUDCD3). The concentration of the C4 amplicon was 
normalized to that of the reference (NUDCD3) amplicon for each sample. We then 
converted the normalized expression in each sample to a percentage of the median 
expression value across all the samples (and this value is plotted on the y-axis in Figure 
3.1a).  
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 We fit a linear model to test association of C4A copy number (measured using 
ddPCR, as described in Chapter 2) to C4A expression in LCLs. We analyzed samples of 
two different ancestries, HapMap CEU and YRI. The heterogeneity in effect of copy 
number on expression across the two sets of samples was not statistically significant (p 
= 0.10), and we did a combined analysis of the samples, using ancestry as a binary 
covariate in our linear model. In order to relate C4 structures to C4A expression, we fit a 
linear model for each of the four common C4 structures, with the dosage (0, 1, or 2) of 
the C4 structure per diploid genome (which we had determined for these samples in 
Chapter 2), as the explanatory variable. The coefficient form the linear regression model, 
β, is plotted in Figure 3.1b.  
 
Quality control   
QC was performed in PLINK133 and the following set of SNPs and samples were 
removed: (i) variants within the duplicated C4 locus (hg 19); (ii) samples missing 
genotypes for more than 5% of SNPs; (iii) SNPs with minor allele frequency less than 
1%; (iv) SNPs missing genotypes across more than 2% of the samples; (v) SNPs that 
had differential rates of missing genotypes between cases and controls (p < 10-5 from a 
Fisher’s exact test); (vi) SNPs whose genotypes were not in Hardy-Weinberg equilibrium 
(p < 10-5); (vii) SNPs whose allele minor allele frequency was more than 15% different 
from its frequency in the reference panel for imputation; and (viii) transversion SNPs 
(A/T and G/C) with minor allele frequency > 0.35 (these SNPs were removed as it can 
be problematic to determine whether they have the same strand assignment as SNPs in 
the reference panel for imputation). After applying these QC filters, 3,664 SNPs 
remained that were in common with our HapMap CEU reference panel for imputation of 
C4 structural variation.  
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Determining copy number of C4A using ddPCR 
 We used ddPCR to measure copy number of C4A in the SLE case-control 
samples using reaction conditions detailed in Chapter 2. An assay designed to an 
ultraconserved element was used as a control and was run with the C4A assay for each 
sample (oligonucleotide sequences provided in Supplemental Table 1).  
We flagged samples that met any of these criteria: (i) number of droplets generated 
< 4,000; (ii) width of 95% Poisson confidence interval > 1; (iii) concentration of the 
control locus < 10 copies per µl; and (iv) a difference of > 0.3 between the copy number 
estimated from ddPCR and the nearest integer, after applying a correction factor on a 
plate-by-plate basis.  We calculated a correction factor for each plate of samples as 
follows. The absolute copy number estimate was divided by the value rounded to the 
nearest integer for each sample. A median of these measurements defined a correction 
factor from the first iteration, which was then used to multiply the original set of copy 
number estimates. A new correction factor was calculated from these corrected copy 
number estimates. We repeated this loop until the correction factor converged (typically 
within the first 5 iterations).  
Excluding the samples that were flagged using the QC criteria described above 
could result in a differential missing rate between cases and controls, potentially skewing 
the association statistic. We inferred copy number for such samples with high-
confidence by integrating the available ddPCR data for these samples together with their 
SNP genotypes, along with data for samples whose copy number calls from ddPCR was 
unambiguous. For samples that were flagged during QC, we considered a copy number 
of x and x+1 as being equally likely, where x is the truncated value (e.g., 2) of the copy 
number estimate from ddPCR (e.g., 2.45). Then, as described in Chapter 2, we provided 
a vector of genotype likelihoods as input for phasing in Beagle113 (version 4). Using the 
surrounding SNP genotypes for these samples together with the deterministic inferences 
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of copy number from ddPCR for the vast majority of the samples, we were able to obtain 
posterior genotype probabilities that readily identified the most likely genotype for each 
sample.  
 
Imputation of C4 structural variants  
 We imputed C4 structural variants using the reference panel we created in 
Chapter 2, consisting of 222 haplotypes from HapMap CEU samples and 7,751 SNPs, 
using Beagle115. For imputation of copy number of C4 CNVs, we encoded the structural 
forms of C4 as a series of pseudo-biallelic variants, as described in Chapter 2. In order 
to test association independently to each C4 structure segregating on a different HLA 
haplotype background (defined based on 250 kb of SNPs around the C4 locus), we 
explicitly encoded these as separate alleles in the reference panel. For example, the AL-
BS structures segregating on the 5 different HLA haplotypes were encoded as AL-BS 1, 
AL-BS 2, AL-BS 3, AL-BS 4 and AL-BS 5 in the reference panel. We then used a narrow 
window of SNPs (100 SNPs on either side of the C4 locus) to impute these structural 
alleles into the SLE case-control data.  
 
Imputation of HLA classical alleles  
 We used two reference panels for the imputation of HLA classical alleles – a 
HapMap CEU panel consisting of both classical alleles as well as C4 structural variants 
(n = 118 haplotypes) and a much larger panel (n = 9,956 haplotypes)114 based on data 
collected by the Type 1 Diabetes Genetics Consortium (T1DGC), which did not include 
C4 structural variants. We performed imputation using Beagle115. The CEU reference 
panel for the imputation of HLA classical alleles from Jia et al.114 contained 90 
individuals. We had C4 structural variation data for 63 of these samples and were able to 
place C4 structural variants onto haplotypes with HLA classical alleles and SNPs for 59 
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samples.  The correlation (r2) in the genotypes of HLA-DRB1*03:01 and *15:01 imputed 
based on these two reference panels was 0.98 and 0.86, respectively. We used the 
imputed data from the CEU reference panel to infer haplotype relationships between C4 
structural variants and classical alleles, and used the imputed data based on the much 
larger T1DGC reference panel for association analysis.  
 
Association analysis  
 We performed association analyses in a logistic regression framework. To test 
association to copy number of C4 structural features (C4A, C4B, C4L, C4S), we used 
the probabilistic dosages obtained from imputation. We tested association and 
calculated effect size for each C4 structural allele (e.g., AL-BL 1, AL-BL 2, etc.) 
separately by including the dose of that allele per diploid genome (0, 1, or 2) as an 
independent variable in the regression. We obtained an estimate of effect size for each 
C4 structure (e.g., AL-AL) across all alleles that contained that given structure (e.g., AL-
AL 1 and AL-AL 2), by performing an inverse variance meta-analysis based on the effect 
size and standard error associated with each C4 allele that contained the given 
structure. We included dosages of the risk allele of HLA-DRB1*03:01 and *15:01 as 
covariates when testing association to C4 conditional on these variants. In order to 
model a dominant effect of *03:01 and *15:01 on SLE risk, we assigned a dose of 0 for 
individuals lacking a risk allele and a dose of 1 for those who had at least 1 copy of the 
risk allele. We included DNA source (blood [n = 10,772] or buccal [n=325]) as a 
covariate in all of the association analyses. 
	   
 
 
 
 
 
 
Chapter 4 
Structural variation in C4, a gene involved in 
synaptic pruning, affects gene expression in the 
brain and influences risk of schizophrenia 
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Introduction 
The association of the HLA locus to schizophrenia has been a topic of 
investigation since 197462. This association is the strongest, most well replicated, and 
most complex finding from genome-wide association studies (GWAS) of schizophrenia, 
as described in Chapter 1. In the latest GWAS meta-analysis of schizophrenia22, the 
HLA association signal spanned several megabases and dozens to hundreds of genes, 
and no single variant within the locus could fully explain the association. It remains 
unclear which gene(s) and functional allele(s) underlie the association of the HLA locus 
to schizophrenia.  
Schizophrenia has a typical age of onset in late adolescence to early 
adulthood134, and the human brain undergoes significant morphological changes in the 
years leading up to this period135. Studies of postmortem human brain tissue have 
identified a reduction in dendritic spine density in multiple cortical regions in 
schizophrenia136. Genetic as well as epidemiological evidence have suggested a 
contribution of both neuronal and immunological processes to schizophrenia22, 42, 67, 137, 
138 but whether and how these processes may be mechanistically linked in the 
pathogenesis of schizophrenia is unknown.  
We hypothesized that complex structural variation in the C4 gene contributes to 
the HLA association signal in schizophrenia based on the following lines of reasoning. 
First, whereas the association of other phenotypes, such as rheumatoid arthritis, to the 
HLA locus has been ascribed to coding variants within classical HLA genes139, these 
variants do not associate as strongly to schizophrenia as SNPs elsewhere in the 
extended HLA locus35, suggesting that the causal variation could reside in other gene(s) 
within the locus. Second, CSMD1 (CUB and Sushi multiple domains 1), which functions 
in promoting degradation of the activated fragment of C499 and inhibiting the classical 
complement pathway, was among the first loci to be identified from GWAS of 
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schizophrenia48. Third, other genes that function in the complement pathway, C1Q, C3, 
and CR3 (complement receptor 3), have been shown to play a role in the elimination of 
synapses during neurodevelopment104, 105, a process that might contribute to the 
reduction in spine density in patients with schizophrenia136.   
We also reasoned that the complex form of structural variation in C4 would 
present a powerful opportunity to investigate association to the HLA locus. The strong 
correlation between HLA SNPs has made it challenging to determine which variant(s) 
are responsible for driving the association to this locus. In contrast, the fact that the 
correlation of C4 structural variants to individual SNPs is only partial (as described in 
Chapter 2) could provide additional power to assess independence of association to C4 
from association to other variants in the HLA locus.  
  
C4A expression in the brain increases with both C4A and C4L copy number 
 We measured expression of C4A in postmortem brain samples from the Stanley 
Medical Research Institute (SMRI) collection, consisting of tissue from 5 brain regions 
(anterior cingulate cortex, orbital frontal cortex, parietal cortex, cerebellum, and corpus 
callosum) from 105 individuals. We used droplet-digital PCR (ddPCR, described in 
Chapter 2) to measure copy number of C4 structural features in these samples and 
measured gene expression of C4A using reverse-transcriptase ddPCR (RT-ddPCR, 
described in Chapter 3). 
 C4A and C4L copy number both associated to C4A expression (p <10-10 from a 
linear model, Figure 4.1a and 4.1b). Since C4A and C4L copy number were correlated 
(r2 = 0.50 across the 105 samples), we next analyzed them conditionally upon each 
other. We regressed C4A expression against C4A copy number, and then fitted these 
residuals to C4L copy number. C4L copy number associated to C4A expression even 
after removing the effect of C4A copy number in this manner (p < 0.01, Figure 4.1c). In  
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Figure 4.1. Relationship between C4 structural variation and C4A expression in 
postmortem human brain tissue. (a) Association of C4A copy number to C4A 
expression. (b) Association of C4L copy number to C4A expression. (c) Association of 
C4L copy number to C4A expression after normalizing out the effect of C4A copy 
number. Each point in these plots represents a composite measurement of gene 
expression for an individual across five brain regions (details provided in the Methods 
section). P-values shown are from a linear model fitting expression to copy number.  
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a linear model that included both C4A and C4L copy number as explanatory variables, 
the effect size, β, per copy of C4A and C4L was nearly identical (β = 20.45 for C4A; 
20.50 for C4L). C4A and C4L copy number, together, explained 42% of the variance in 
C4A expression.  
 We then related C4A expression to the four common C4 structures. We 
calculated an effect size, β, associated with each of these four structures from fitting 
C4A expression to the number of chromosomes per diploid genome that carried that 
structure (0, 1, or 2). The resulting pattern of association was consistent with a 
contribution of C4L copy number in addition to C4A copy number to expression of C4A 
across multiple brain regions (Figure 4.2a-f). This result was in contrast to the finding in 
lymphoblastoid cell lines (Chapter 3, Figure 3.1b), in which only C4A copy number 
associated to C4A expression.  
 
Variation in the expected expression of C4A and two additional, statistically 
independent effects contribute to the HLA association signal in schizophrenia  
We analyzed the association of the HLA locus to schizophrenia in 40 cohorts 
(totaling 28,799 schizophrenia cases and 35,986 controls of European ancestry) from 
the Psychiatric Genomics Consortium22. We used the HapMap CEU reference panel that 
we created for imputation of C4 structural variants (described in Chapter 2) for 
evaluating the contribution of C4 to schizophrenia risk. We performed a mega-analysis 
that utilized individual-level genotype data from all of the samples, and tested 
association in a logistic regression framework that included study indicator variables to 
account for cohort-specific effects and principal components to control for population 
stratification.  
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Figure 4.2. Association of the four common C4 structures to C4A expression in (a) the 
cingulate cortex, (b) orbital frontal cortex, (c), parietal cortex, (d) cerebellum, and (e) 
corpus callosum. (f) Association to a composite measure of gene expression across the 
five brain regions. β measures the effect size calculated from fitting C4A expression to 
the number of chromosomes (0, 1, or 2) carrying that C4 structure per diploid genome.  
 
We tested association to 7,751 imputed SNPs and identified a strong, diffuse 
association of the extended HLA locus to schizophrenia (Figure 4.3a). The most 
strongly associated variant was rs13194504 (p = 5.5x10-28), an intergenic SNP 4.6 kb 
downstream of the nearest gene, tRNA_ala (transfer RNA Ala). This SNP indexed an 
association to a long (approximately 2 Mb) haplotype on the telomeric end of the 
extended HLA locus (chromosome 6, 27.5-29.5 Mb).  
  Imputed copy number of C4A and C4L also associated strongly to schizophrenia 
(p = 6.3x10-19 for C4A and 7.2x10-23 for C4L). In a joint model, both C4A and C4AL copy 
number remained significant (p = 0.002 for C4A and 1.4x10-7 for C4L). Based on the 
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influence of C4A and C4L copy number on expression of C4A in the brain, we 
hypothesized that the association of schizophrenia to expected C4A expression in the 
brain (E[C4A expression]) would be stronger than its association to C4A or C4L copy 
number alone. We calculated E[C4A expression] based on the linear model derived from 
fitting C4A expression in postmortem brain to C4A and C4L copy number. Consistent 
with our hypothesis, we identified a stronger association of schizophrenia to E[C4A 
expression], with higher expected expression associating to increased risk of 
schizophrenia (p = 6.2x10-25, Figure 4.3a).   
The association to E[C4A expression] was largely independent of the association 
indexed by rs13194504  (r2 = 0.18,  Figure 4.3b and 4.3c). In analyzing these effects in 
a joint model, E[C4A expression] associated to schizophrenia more strongly than any 
other variant in the HLA locus (p = 2.4x10-10, Figure 4.3d), and rs13194504 remained 
highly significant in a joint model with E[C4A expression] (p = 1.5x10-13, Figure 4.3e).   
  We identified a third, statistically independent effect in the centromeric end of the 
extended HLA locus. The variant most strongly associated in a joint model with 
rs13194504 and E[C4A expression] was rs210133 (p = 1.8x10-8, Figure 4.3f), an 
intergenic SNP 3.5 kb downstream of BAK1 (BCL2-antagonist/killer 1). In addition, 
rs9461856, an intronic SNP in SYNGAP1 (synaptic Ras GTPase activating protein 1) 
was also highly significant (p = 1.0x10-7) in a joint model with rs13194504 and E[C4A 
expression], but was only weakly correlated with rs210133 (r2 = 0.21). No genome-wide 
significant associations remained in the HLA locus conditional on rs13194504, E[C4A 
expression] and rs210133 (Figure 4.3g), but all three effects remained highly significant 
in a joint model (p = 1.5x10-13, 8.9x10-9, and 1.8x10-8, respectively).  
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Figure 4.3. Association of the HLA locus to schizophrenia. (a) Association of 
schizophrenia to 7,751 imputed SNPs and imputed copy number of C4 structural 
features based on analysis of 28,799 schizophrenia cases and 35,986 controls of 
European ancestry. E[C4A expression] indicates the expected expression of C4A in the 
brain, calculated based on imputed copy number of C4A and C4L, using the linear 
model built from relating C4 structural variation to C4A expression in human postmortem 
brain samples. (b) Association of schizophrenia to SNPs in the HLA locus colored by 
correlation (r2) to rs13194504, the SNP most strongly associated to schizophrenia in the 
HLA locus. (c) Association of schizophrenia to SNPs in the HLA locus, colored by 
correlation to E[C4A expression]. Association to SNPs in the HLA locus with (d) 
rs13194504, (e) E[C4A expression], (f) rs13194504 and E[C4A expression], (g) 
rs13194504, E[C4A expression], and rs210133 as covariates in the logistic regression 
model. Dashed red line indicates the threshold for genome-wide significance  
(p = 5x10-8).  
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Figure 4.3 (continued) 
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C4 structures associate to schizophrenia in proportion to their effect on C4A 
expression, with minimal influence of their HLA haplotype background  
 We next analyzed association of schizophrenia to C4 structures, taking into 
account variation in their HLA haplotype backgrounds, in order to distinguish between 
the effect of C4 structure and effects elsewhere in the HLA locus. We encoded C4 
structures segregating on different HLA haplotypes (Chapter 2, Figure 2.10) as separate 
alleles in our reference panel for imputation. We then imputed these C4 structural alleles 
into 28,799 schizophrenia cases and 35,986 controls analyzed above, using the 
surrounding SNP genotype data as the backbone for imputation, and evaluated 
association to each of these alleles.  
Across 11 C4 structural alleles (each present at a frequency of more than 3% in 
our reference panel), the odds ratio was defined by the C4 structure that it contained, 
with minimal influence of the HLA haplotype on which it segregated (Figure 4.4a). This 
allelic series of effects on schizophrenia risk corresponded to the effect of C4 structures 
on C4A expression in the brain (Figure 4.2) – across the four common C4 structures, the 
greater the C4A expression in the brain, the greater the risk of schizophrenia. The effect 
sizes associated with the four common C4 structures spanned an odds ratio of 0.84 
(95% CI: 0.81- 0.87) associated with BS to 1.09 (95% CI: 1.05-1.13) associated with AL-
AL. The correlation of effect sizes across the 11 C4 alleles to the number of copies of 
C4A and C4L that each allele contained was statistically significant (p = 5.7x10-5). In 
contrast, the heterogeneity of effect sizes across alleles that contained the same C4 
structure on different HLA haplotypes was not statistically significant (p = 0.55 for AL-AL 
alleles; p = 0.93 for AL-BL alleles; and p = 0.06 for AL-BS alleles).  
 We then analyzed the association of schizophrenia to C4 in a joint model with 
rs13194504, the variant that indexed the association to the telomeric end of the 
extended HLA locus. Across the 11 C4 structural alleles, the allelic series of effects  
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Figure 4.4. Association of C4 structures on different HLA haplotype backgrounds to 
schizophrenia. (a) The effect size associated with each C4 structural allele was 
predicted by its C4A and C4L copy number and the association of C4 structures to C4A 
expression in the brain (Figure 4.2). (b) The pattern of association to C4 was preserved 
when including rs13194504 in the model, with a moderation of the effect size associated 
with BS. C4 structures suffixed with a different number (e.g., AL-BL 1 and AL-BL 2) 
represent alleles with the same structural content segregating on different HLA 
haplotype backgrounds, and they correspond to the annotation in Figure 2.10 in Chapter 
2. The diamond symbols in bolder colors represent the effect size from a meta-analysis 
of the effect of each allele containing the same C4 structural content.  
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remained intact in a joint model that included rs13194504 (Figure 4.4b). The main effect 
of including rs13194504 in the model was to moderate the outsized protective effect 
associated with the BS structure. 
 
C4 structural variation, analyzed using ddPCR, associates strongly to 
schizophrenia 
We next sought to evaluate the accuracy of our imputation-based results using 
molecular measurements of C4 copy number from ddPCR. We measured copy number 
of C4A, C4L, and C4S in 2,195 cases and 2,485 controls of Swedish ancestry, one of 
the largest samples from the PGC data set. We were also able to infer copy number of 
C4B and total C4 from these measurements, given the following relationship: copy 
number of C4A + C4B = C4L + C4S = total C4.  
Across the samples that were genotyped using ddPCR, the imputed copy 
number for C4A and C4L correlated with the ddPCR-based copy number measurements 
with an r2 of 0.59 and 0.81, respectively. These results were consistent with the 
predictions from leave-one-out trials described in Chapter 2 (Figure 2.12). E[C4A 
expression] based on imputed genotypes correlated with that based on ddPCR 
measurements with an r2 of 0.78.     
The association of schizophrenia to C4L copy number (p = 8.4x10-8), based on 
ddPCR measurements, was at least as strong as to any individual SNP in the extended 
HLA locus (Figure 4.5a). E[C4A expression], which was calculated based on ddPCR-
derived copy number measurements, also associated strongly (p = 1.1x10-6). We 
determined the C4 structures underlying the copy number of C4 structural features 
measured in each individual, using ddPCR measurements together with SNP genotype 
data for these samples (as described in the Methods section). We tested association to 
the four most common C4 structures, and the effect size associated with these  
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structures spanned a wide range with an odds ratio of 0.74 (95% CI: 0.65-0.85) for BS to 
1.17 (95% CI: 1.07-1.27) for AL-BL (Figure 4.5b). The pattern of association of 
schizophrenia to these four structures was in proportion to their effect on C4A 
expression in the brain (Figure 4.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5. Association analysis in 2,195 cases and 2,485 controls of Swedish ancestry 
based on molecular measurements of C4 copy number using ddPCR. (a) Association of 
schizophrenia to copy number of C4 structural features, E[C4A expression], and to 
SNPs in the extended HLA locus. (b) Association to common C4 structures that were 
determined using ddPCR-based copy number measurements together with SNP 
genotype data.  
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C4A expression is higher in postmortem brains samples from patients with 
schizophrenia than in unaffected controls 
Based on the finding that C4 structures associating with increased expression of 
C4A also associated with increased risk of schizophrenia, we hypothesized that the 
expression of C4A would be higher in postmortem brain samples from patients with 
schizophrenia than in unaffected controls. To test this prediction, we related 
measurements of C4A expression in the SMRI cohort (35 unaffected controls, 35 
patients with schizophrenia, 20 patients with bipolar disorder with psychotic features and 
10 patients with bipolar disorder without psychotic features), to their clinical diagnosis. 
C4A expression across the five brain regions was higher in samples from patients with 
schizophrenia than in those from unaffected controls (p = 0.002, Figure 4.6a). The 
difference in expression of C4A between patients with schizophrenia and bipolar 
disorder patients with psychosis was not statistically significant (p = 0.18), but the 
difference in expression between bipolar disorder patients with and without psychosis 
trended toward significance (p = 0.06).  
Since C4A and C4L copy number associated to both case-control status as well 
as expression, we next asked whether the difference in C4A expression between 
unaffected controls and patients with schizophrenia would still be significant after 
removing the effect of C4 structural variation. We compared residual expression of C4A, 
after fitting it to C4A and C4L copy number, across the four diagnostic groups. The 
difference in expression between unaffected controls and patients with schizophrenia 
remained statistically significant (p = 0.003, Figure 4.6b) and the difference in 
expression between bipolar disorder patients with and without psychotic features was 
nominally significant (p = 0.04).  
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Figure 4.6. Expression of C4A in postmortem brain samples from control individuals (n= 
35) and patients with schizophrenia (n = 35), bipolar disorder with psychotic features (n 
= 20) and bipolar disorder without psychotic features (n = 10), (a) before and (b) after 
removing the effect of C4A and C4L copy number on C4A expression. A composite 
measure of C4A expression across the five brain regions analyzed was used in these 
analyses. P-values are from a Mann-Whitney test with alternative hypotheses of lower 
expression in control individuals compared to patients with schizophrenia; unequal 
expression between patients with schizophrenia and bipolar disorder with psychosis; and 
higher expression in patients with bipolar disorder with psychotic features compared to 
those with bipolar disorder without psychotic features.  
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Figure 4.6 (continued) 
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We then evaluated whether the expression of other genes that function in the 
classical complement pathway was different between unaffected controls and patients 
with schizophrenia, and the findings are summarized in Table 4.1. The expression of 
C4B, a paralog of the C4A gene that is more than 99% identical at the nucleotide level, 
was not different between the two groups (p = 0.37, before correcting for copy number of 
C4B; p = 0.17 after correcting for copy number). Total expression of C4 (the sum of C4A 
and C4B expression), however, was higher in patients with schizophrenia compared to 
unaffected controls, before as well as after correcting for C4 copy number (p = 0.009 and 
0.007, respectively). The expression of C1QB, which functions upstream of C4 in the 
classical complement pathway (Chapter 1, Figure 1.4), showed a trend toward higher 
expression in patients with schizophrenia (p = 0.09). Similarly, C2, which also functions 
in the classical complement pathway, achieved a nominal level of significance (p = 0.04) 
for higher expression in patients with schizophrenia. We then asked whether the 
expression of CSMD1, which encodes an inhibitor of the classical complement 
pathway98, 99, shows differential expression in the opposite direction as C4A, C1QB, and 
C2 – with higher expression in controls compared to patients with schizophrenia. Of the 
two brain regions analyzed, the expression was indeed higher in unaffected controls in 
the cingulate cortex (p = 0.002), but not in the cerebellum (p = 0.76). Expression of C3, 
which functions in the alternative complement pathway in addition to the classical 
pathway, did not differ between cases and controls across the four brain regions tested 
(p = 0.34).  
 
C4 expression increases in the brain as mice and humans enter adulthood 
In order to understand how expression of C4 varies with age – and particularly 
around the period corresponding to the typical age of onset of schizophrenia – we 
profiled its expression in brains from wild type mice across developmental age groups,  
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Table 4.1. Differences in expression of genes that function in the early steps of the 
complement pathway in postmortem brain samples from unaffected controls and 
patients with schizophrenia. P-values are from a Mann-Whitney (non-parametric) test of 
the specified alternative hypothesis, testing association across a composite measure of 
expression across the indicated brain regions unless otherwise stated. a Before 
removing the effect of variation in copy number; b after removing the effect of variation in 
copy number. 
Gene Function in the complement pathway Brain regions tested Hypothesis p-value  
C4A 
Part of the classical 
pathway C3 convertase, 
an enzymatic complex 
that activates the central 
component of the 
complement pathway 
 
Cingulate cortex 
Orbital frontal cortex 
Parietal cortex 
Cerebellum 
Corpus callosum 
 
Higher 
expression in 
patients with 
schizophrenia 
0.002a 
0.003b 
 
C4B Part of the classical pathway C3 convertase ‘’ “ 
0.37a 
0.17b 
C4 (combined 
expression of 
C4A and 
C4B) 
 ‘’ “ 0.009
a 
0.007b 
C1QB 
Initial component of the 
classical complement 
pathway; part of the 
complex that activates C4 
“ “ 0.09 
C2 
Part of the classical 
pathway C3 convertase, 
together with C4 
“ “ 0.04 
CSMD1 
An inhibitor of the 
classical complement 
pathway 
Cingulate cortex 
Cerebellum 
Higher 
expression in 
unaffected 
controls 
0.002 
(cingulate 
cortex) 
0.76 
(cerebellum) 
C3 
Central component of the 
complement pathway; 
functions in both 
alternative and classical 
pathways of the 
complement system 
Cingulate cortex 
Parietal cortex 
Cerebellum 
Corpus callosum 
Higher 
expression in 
patients with 
schizophrenia 
0.34 
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using RT-ddPCR. C4 expression increased with age across the age groups analyzed, 
between postnatal day 3 (P3) to P60, in the mouse midbrain (Figure 4.7a). We also 
measured C4 expression in other brain regions from P28 and P60 animals and found a 
two-fold increase in expression between these two age groups in the hippocampus, but 
not in the cerebellum, temporal cortex, or visual cortex. We then analyzed human C4 
expression in the publicly available BrainSpan data set140, which contains transcriptome-
wide expression data from RNA-sequencing analysis of the developing human brain. 
Despite not having been corrected for variation in copy number (and genetic variation 
elsewhere in the genome) across individuals, a pattern of increasing C4 expression into 
adulthood was identifiable in the dorsolateral prefrontal cortex (Figure 4.7b) and 
ventrolateral prefrontal cortex (Figure 4.7c) as well as in the striatum, anterior cingulate 
cortex and orbitofrontal cortex, but not in other regions (cerebellar cortex, and primary 
visual cortex).  
 
Neurons and microglia express complementary components of the complement 
pathway 
We next sought to identify which cell type(s) within the brain express C4A and 
other genes of the complement pathway. We profiled their expression using RT-ddPCR 
in cultured primary human cortical neurons, microglia, astrocytes, and oligodendrocytes 
(details about the source of these cells are provided in the Methods section). Given the 
role of microglia as the resident immune cell type of the brain, we expected complement 
genes to be expressed in these cells. Indeed, they expressed relatively high levels of 
C1QB, C2, and C3, but little-to-no C4A, C4B, or CSMD1 (Figure 4.8). C4A was, 
however, expressed in neurons (approximately eight-fold higher than its expression in 
microglia) as well as in oligodendrocytes. Neurons and oligodendrocytes also expressed 
CSMD1.        
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Figure 4.7. Expression of C4 across developmental ages in mouse and human brains. 
(a) Expression of C4 in the midbrain of C57BL/6 wild type mice, as measured by RT-
ddPCR. Error bars indicate 95% Poisson confidence intervals. Age in postnatal days is 
shown on the x-axis. Each point represents a measurement from a different mouse. (b) 
Expression of human C4 in the dorsolateral prefrontal cortex and (c) ventrolateral 
prefrontal cortex based on RNA-sequencing data from the BrainSpan data set140. Unlike 
the mouse data in (a), in which copy number of C4 did not vary from animal-to-animal, 
the human data in (b) and (c) are not corrected for variation in C4 copy number. Periods 
corresponding to fetal development are shown are blue, childhood and adolescence in 
purple, and adulthood (age > 18 years) in red. pcw, post-conception weeks; mos, 
months; yrs, years.  
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Figure 4.8. Expression of complement genes in cultured primary human neurons, 
microglia, astrocytes, and oligodendrocytes. Error bars represent 95% Poisson 
confidence intervals from RT-ddPCR.  
 
Given the low baseline expression of C4A in microglia, we tested whether its 
expression could be upregulated upon stimulation of microglia with lipopolysaccharide 
(LPS), a component of the outer membrane of Gram-negative bacteria, or polyinosine-
polycytidylic acid [poly(I:C)], a viral-like double-stranded RNA. Although the expression 
of C1QB, C2, and C3 was detected at a 2-4 fold higher level in microglia treated with 
LPS (Figure 4.9a) or poly(I:C) (Figure 4.9b), the expression of C4A and C4B remained 
low.  
The finding that C4A was expressed in different cell types than C1QB, C2, and 
C3 led us to investigate whether the expression of these genes was still correlated 
across samples. To test this, we analyzed their expression in 105 postmortem brain  
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Figure 4.9. Expression of complement genes in primary human microglia treated with 
(a) lipopolysaccharide (LPS), and (b) polyinosine-polycytidylic acid [poly(I:C)] with 
concentrations and durations of treatment as indicated. Error bars are from 95% Poisson 
confidence intervals. Expression of C1QB, C2, and C3 was detected at 2-4 fold higher 
levels with treatment, whereas expression of C4A and C4B remained low (note the 
variation in y-axis scales). The 24-hour time point from treatment with poly(I:C) is not 
shown for C1QB as the expression was too high to be reliably quantified using RT-
ddPCR.  
 
samples (from the SMRI collection). We first removed the effect of copy number 
variation on expression by calculating the residuals from fitting C4A expression to C4A 
and C4L copy number, and tested correlation between these residuals and the 
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expression of other genes. As expected, residual C4A expression correlated strongly 
with residual C4B expression (Figure 4.10a). In addition, residual C4A expression also 
correlated to expression of C1QB (Figure 4.10b),  C2 (Figure 4.10c), and to a lesser 
extent, C3 (Figure 4.10d).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10.  Correlation between expression of C4A and other genes of the 
complement pathway in postmortem brain samples. Expression of (a) C4B, (b) C1QB, 
(c) C2, and (d) C3 are plotted against C4A expression, based on a composite measure 
of gene expression across multiple brain regions. Residual expression refers to the 
residuals values that remained after fitting gene expression to copy number in a linear 
model.  
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Mice lacking C4 have a deficit in synaptic pruning that is rescued by human C4 
Previous work has identified a role for C1q, C3, and CR3 (complement receptor 
3, a receptor for C3) in synaptic pruning104, 105, the process by which the excessive 
number of synapses that are initially formed during development are eliminated, while a 
subset are maintained and strengthened. The position of C4 between C1q and C3 in the 
classical complement pathway (Chapter 1, Figure 1.4) suggests that C4 is also likely to 
contribute to synaptic pruning. However, little is known about the expression of C4 
during the process of synaptic refinement, and whether C4 plays a role in synapse 
elimination has not yet been investigated.  
In order to test whether C4 contributes to synaptic pruning, we used the well-
studied retinogeniculate system104, 105, 141, 142. In this system, there is initially an 
overabundance of synapses formed between retinal ganglion cells (RGCs) and neurons 
within the dorsal lateral geniculate nucleus of the thalamus (dLGN), with dLGN neurons 
being innervated by up to ten RGC axons. Inputs from each eye compete for synapses 
in the dLGN, with some synapses weakening and becoming eliminated and others 
becoming mature.  Within the first 10 days, axons from RGCs organize into eye-specific 
territories in the dLGN and by postnatal day 30, each dLGN relay neuron only receives 
input from 1-2 RGC axons.  
We visualized the segregation of inputs from RGCs in the dLGN using an 
anterograde tracing technique in which mice receive an injection in each eye with a 
different colored dye conjugated to the cholera toxin-β subunit. We quantified the degree 
of overlap between inputs from each eye in the dLGN in P10 mice using an R-value 
analysis143. The R-value is the log10 ratio of fluorescence intensity from the ipsilateral 
and contralateral channel, log10(Fipsi/Fcontra). The higher the variance of this value, the 
greater the degree of segregation, and lower the overlap between the ipsilateral and 
contralateral inputs. Compared to wild type littermates, C4 -/- mice had lower R-value 
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variance (p = 0.004, Mann-Whitney test, Figure 4.11a,b), indicating greater overlap 
between RGC inputs from each eye. The degree of deficit in C4 -/- was similar to that 
previously reported for C1q -/- and C3 -/- mice104, 141. In addition, C4 heterozygote mice, 
with one wild type copy of mouse C4, had a significantly higher R-value variance than 
C4 -/- mice (p = 0.003, Figure 4.11b). Wild type mice had a higher mean R-value 
variance than C4 heterozygote mice, but this difference did not reach statistical 
significance (p = 0.10) 
We then tested whether human C4, with its endogenous regulatory sequence 
retained, could rescue this phenotype in C4 -/ -mice. We generated transgenic mice that 
contained human C4 in a background of mouse C4 -/-, using a human BAC clone that 
contains one copy each of C4AL and C4BL (AL-BL). Screening of transgenic mice for 
copy number of human C4 revealed the presence of two copies of C4AL and one copy 
of C4BL (potentially arising from a recombination event resulting in a partial duplication). 
Compared to C4 -/- littermates, these transgenic mice had a significantly higher R-value 
variance (p = 0.004, Figure 4.11 b), similar to wild type mice.  
 
Discussion 
We have identified an allelic series of structural variants in the C4 gene that 
contributes to the risk of schizophrenia and its association to the HLA locus. We found 
that C4 structures with higher copy number of C4A and C4L associated with increased 
risk of schizophrenia, resembling their influence on C4A expression in postmortem 
human brain tissue. Furthermore, we developed a novel form of association testing that 
exploited the segregation of C4 structures on different HLA haplotype backgrounds to 
show that their effect on schizophrenia risk is unlikely to be a result of variation 
elsewhere in the HLA locus. We have also shown that both mouse and human C4 
contribute to synaptic pruning in the mouse retinogeniculate system.  
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Figure 4.11. Mice lacking C4 exhibit a synaptic pruning deficit that is rescued by human 
C4. (a) Representative images of the dorsal lateral geniculate nucleus (dLGN) from wild 
type, C4 -/-, and C4 transgenic mice in which cholera toxin-conjugated dyes of two 
different colors were intraocularly injected. The C4 transgenic mice used in these 
experiments had three copies of human C4 (two C4A and one C4B; all three genes were 
of the long form, C4L) in a mouse C4 -/- background. The images are pseudocolored to 
show the R-value for each pixel. The R-value is the log10(Fipsi/Fcontra), where Fipsi is the 
fluorescence intensity in the ipsilateral channel and Fcontra is the fluorescence in the 
contralateral channel. (b) Quantification of the variance of the R-value for each group. 
WT, two wild type copies of mouse C4; C4 het, 1 wild type copy of mouse C4; C4 -/-, 
absence of wild type mouse C4. n = 5 WT, 7 C4 heterozygotes and 5 C4 -/- mice in the 
first set of littermates; 5 WT and 5 C4 transgenic mice in the second set of littermates. P-
values are from a Mann-Whitney test with an alternative hypothesis of higher R-value 
variance in WT compared to C4 heterozygotes or C4 -/- mice; higher in C4 heterozygotes 
compared to C4 -/-; higher in C4 transgenic mice compared to C4 -/-.  
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Genome-wide association studies of schizophrenia and other phenotypes 
typically identify loci that harbor multiple genes (3-4 on average in the latest GWAS 
meta-analysis of schizophrenia22). In most cases, neither the identity of the genes and 
variants within these loci that are driving the association nor their functional 
consequences are known. Similarly, studies of rare CNVs in schizophrenia have 
identified associations to large genomic segments, containing dozens of genes (e.g., 
deletions of the 22q11.2 locus in schizophrenia affect the dosage of up to 43 genes37). In 
contrast, our work has identified a series of alleles within a single gene that contribute 
both to its expression and to the risk of schizophrenia.  
The finding that structural variation in C4 influenced its expression in the brain 
enabled us to explicitly model the effect of these variants on C4A expression when 
testing their association to schizophrenia. Given that our analysis of the PGC data set 
was based on imputation, and that the imputed genotypes imperfectly capture the effect 
on C4A expression, it is possible that the association could be strengthened with more 
accurate genotyping of C4 structural variation.  
 Our results revealed that copy number of C4A as well as C4L contributed to C4A 
expression in the brain and to schizophrenia risk. While it is expected that the dosage of 
the C4A gene would affect its expression in the brain (as it did in lymphoblastoid cell 
lines, Chapter 3), the finding that the number of copies of the Human Endogenous 
Retrovirus (HERV), the 6.4 kb insert that defines the C4L form, correlated with C4A 
expression is more surprising. However, this result is consistent with the recent finding 
that a HERV insertion in another gene, PRODH, is bound by the transcription factor 
SOX2 and serves as an enhancer in the brain144. The influence of HERV copy number 
on C4A expression also suggests a potential functional mechanism by which variation in 
C4L copy number could influence the risk of schizophrenia, but we do not rule out 
alternative mechanisms. For example, the HERV sequence, which is present in an 
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antisense orientation in relation to the C4 transcript, could mediate a gene-environment 
interaction in which variation in its copy number may influence the susceptibility to 
exogenous retroviruses145, 146. In this scenario, the inflammatory response to these 
viruses during susceptible periods of neurodevelopment may influence predisposition to 
later developing schizophrenia.  
In addition to the association of schizophrenia to C4 structural variation, we 
identified two effects within the HLA locus that were not explained by association to 
(imputed) C4 structural variants. The presence of multiple effects in the HLA locus is 
consistent with its outsized strength of association to schizophrenia (Chapter 1, Figure 
1.1b), though independently, the C4 locus and rs13194504 were still among the 
genome's strongest signals (p = 2.4x10-10 and 1.5x10-13, respectively, from a joint 
model).  
The functional variants responsible for the association to rs13194504 and 
rs210133 remain to be identified. rs13194504 indexed a strong association to a long 
haplotype (27.5-29.5 Mb on chromosome 6), and it is possible that variation in class I 
HLA genes contributes to this association. Similar to complement genes, class I genes 
have also been implicated in synapse elimination and they colocalize with synaptic 
markers and with C1q72, 147.  
In a joint model with rs13194504 and E[C4A expression], we identified a third 
genome-wide significant association within the HLA locus, to rs210133 (p = 1.8x10-8) as 
well as a strong association (p = 1.0x10-7) to rs9461856, an intronic SNP in SYNGAP1. 
SYNGAP1 is a component of the postsynaptic density and mutations in SYNGAP1 have 
been found to disrupt maturation of dendritic spine synapses148 and cause an autosomal 
dominant form of mental retardation149, making it a compelling functional candidate.  
We found an increased expression of C4A in postmortem brain samples from 
patients with schizophrenia, compared to unaffected controls. This result was statistically 
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significant even after removing the effect of C4A and C4L copy number on C4A 
expression. A potential explanation for this result is that variation elsewhere in the 
genome that influences the risk of schizophrenia could affect expression of C4A, 
independently of structural variation in C4. However, it is also possible that the increased 
expression of C4A in patients with schizophrenia could be reactive, in response to the 
disease process. We also found a trend toward increased C4A expression in bipolar 
patients with psychotic features compared to those without psychosis. Although this 
result was only nominally significant, it is consistent with findings from genetic studies of 
schizophrenia and bipolar disorder that suggest a shared etiology35.  
In addition to differences in C4A expression between patients with schizophrenia 
and unaffected controls, we also found nominal support for differential expression of 
other complement genes, in the direction expected based on the pattern observed with 
C4A – we observed a trend toward increased expression of C1QB and C2 (both of which 
function together with C4 in the early steps of the classical complement pathway) and 
decreased expression of CSMD1 (which promotes degradation of an activated fragment 
of C4) in patients with schizophrenia. While these differences in expression were 
nominal and could be reactive as opposed to being causally involved in the 
pathogenesis of schizophrenia, the latest GWAS meta-analysis provides stronger 
evidence for the involvement of other complement genes in schizophrenia22. In addition 
to replicating the previously identified association to CSMD1, this study also identified 
associations to the CD46 and CLU loci. CD46 encodes an inhibitory complement 
receptor that functions in the degradation of the activated fragment of C4150, similar to 
CSMD1. CLU also serves as an inhibitor of the complement pathway (among its other 
functions) and has been associated to Alzheimer's disease151.  
  The expression of C4 in the brain increased with age, into adulthood, in both 
mice and humans, similar to a recent finding of an increase in C1q protein with age152. 
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This pattern was observed in some, but not all, brain regions, potentially due to cellular 
compositions and regulatory influences on gene expression differing across the brain 
structures analyzed. In addition, the pattern was less apparent in humans than in mice, 
likely owing to variation in copy number of C4 across individuals as well as differences in 
the precision with which gene expression measurements were made in the mouse and 
human samples. The variation in expression of C4 with age raises the question of 
whether the increase in expression of C4 into adulthood contributes to synapse 
elimination that occurs during adolescence135 and to the age of onset of schizophrenia, 
which is typically in late adolescence to early adulthood. However, this increase in 
expression of C4 around the age of onset could be a coincidental finding as it is possible 
that the pathogenic phenomena that predispose to developing schizophrenia precede 
the age of onset by several years. It also remains to be investigated whether variation in 
expression of C4 could be influenced by hormonal factors, such as hormones of puberty, 
and whether C4A and C4B show different temporal patterns of expression.  
Our results from profiling expression of C4 and other complement genes in 
primary cultures of human CNS cells suggest cell-type specificity in expression of these 
genes, with C1QB, C2, and C3 being expressed by microglia, and C4 by neurons and 
oligodendrocytes. However, there are several caveats to consider in interpreting these 
results. First, the pattern of expression in these cell types may be spatiotemporally 
dynamic in ways that analyzing these cells in vitro may not reveal. Signaling between 
neurons and microglia, for example, could influence the expression of these genes. 
Indeed, the correlation in expression of C4 with C1QB, C2, and C3 in postmortem brain 
tissue is consistent with this scenario and the possibility that there are shared influences 
in the expression of these genes across cell types. Second, profiling expression of these 
genes in different cell types (e.g., excitatory and inhibitory neurons) and from cells 
isolated from multiple brain regions could also reveal a different pattern of expression. 
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Third, the extent to which genetic variation in C4 (as well as elsewhere in the genome) 
affects the pattern of expression in these cell types also remains to be explored. Despite 
these caveats, ongoing immunohistochemistry and in situ hybridization experiments in 
human and mouse brain tissue are providing corroborating evidence for our in vitro 
results.  
The finding that mouse and human C4 contribute to synaptic refinement in mice 
is consistent with the role of C1q, C3, and CR3 in this process. The similar degree of 
deficit in synaptic pruning in the retinogeniculate system across mice deficient in C1q, 
C3, or C4 suggests that the classical (as opposed to the alternative) pathway may be the 
main contributor to this process, given that C1q and C4 function in the classical pathway 
whereas C3 also functions in the alternative pathway. The difference in R-value variance 
was significant between C4 heterozygous mice and C4 -/- mice and the difference 
between wild type C4 mice and C4 heterozygous mice trended toward significance, 
suggesting that the dosage of the C4 gene may influence the degree of synapse 
elimination in the retinogeniculate system, although increased sample sizes will be 
required to investigate this possibility. The role of C4 in synaptic pruning also offers a 
potential biological mechanism that may link genetic variation in C4 to its influence on 
the risk of schizophrenia. This possibility remains to be investigated further by examining 
whether the specific series of human C4 alleles that associate to schizophrenia vary in 
the extent to which they influence this phenotype in mice.   
 
Contributions 
Steve McCarroll coordinated the study and provided guidance and input on all 
aspects of the work. Beth Stevens and Michael Carroll contributed expertise as well as 
reagents for the in vivo experiments in mice and provided significant feedback on other 
aspects of the work. Allison Bialas and Jessy Presumey performed the in vivo 
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experiments in mice. Samuel Rose performed ddPCR analysis of copy number in the 
Swedish cohort. Vanessa Van Doren performed RT-ddPCR assays of gene expression 
in postmortem human brain tissue. Heather de Rivera performed the in vitro assays on 
human CNS cells, with guidance from Allison Bialas. Matthew Baum profiled gene 
expression in mouse brain samples across developmental ages. SNP genotype data 
from the extended HLA locus for the 40 cohorts analyzed was obtained with approval 
from the Psychiatric Genomics Consortium22.  
 
Methods 
Gene expression analysis in postmortem human brain tissue 
We analyzed expression of C4 and other genes of the complement pathway in 
the Stanley Medical Research Institute Array Collection of postmortem human brain 
samples. This collection consists of 35 individuals in each of 3 diagnostic groups 
(schizophrenia, bipolar disorder, and unaffected controls) and samples from 5 brain 
regions (anterior cingulate cortex, orbital frontal cortex, parietal cortex, cerebellum, and 
corpus callosum). Of the 105 individuals, 102 were of European ancestry. We measured 
copy number of C4 structural features in liver and cerebellar DNA samples from these 
individuals using ddPCR (details of this method are described in Chapter 2). We 
measured gene expression using RT-ddPCR, with reaction conditions described in 
Chapter 3 and primer and probe sequences in Supplemental Table 1).  
We normalized the gene expression measurements to the expression of a control 
gene (NUDCD3, NudC domain containing 3) to account for variation in the amount of 
input RNA across samples. For each individual in the collection, we calculated a 
composite measure of expression across brain regions analyzed. In a i x j matrix of i 
individuals and j brain regions, we converted the normalized expression for ith  individual 
to a percentage of the median expression value across all the samples in the jth column. 
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Then, we calculated a median value across j columns for each row, i, to obtain a 
summary value for expression in each individual across multiple brain regions.  
We tested for association between C4A expression and C4A copy number using a 
linear model: 
 C4A expressioni = β x (C4A copy numberi) + θ 
where C4A copy numberi is the diploid copy number for the ith individual, β is the additive 
effect per copy of C4A on C4A expression, and θ is a constant (intercept). In order to 
evaluate whether C4L copy number associated to expression of C4A independently of 
C4A copy number (with which it is correlated), we took the residuals from the model 
above and fit those to C4L copy number:  
Residual(C4A expression)i =  β x (C4L copy numberi) + θ 
To calculate the effect of each of the four common C4 structures on expression of C4A, 
we fit C4A expression to the dosage of that structure 
C4A expressioni = βj x (dosei,j) + θ 
where dosei,j is the number of chromosomes in each diploid genome i that carry the 
structure j. To determine the C4 structural genotype for each individual in the SMRI 
collection, we integrated copy number data for each C4 structural form (C4A, C4B, C4L, 
and C4S) from ddPCR together with SNP genotypes for these samples (from the 
Illumina Omni 2.5 SNP microarray). For each individual, we enumerated the list of 
structural genotypes consistent with the set of copy numbers of C4 structural features, 
based on the 15 C4 structures that we identified in the HapMap CEU population sample 
in Chapter 2 (Figure 2.8). For example, if the copy number in a diploid genome of C4A, 
C4B, C4L, and C4S were 1, 2, 2, and 1, respectively, in an individual, the only structural 
genotype consistent with this set of copy numbers is AL-BS/BS. In contrast, if the copy 
number of C4A, C4B, C4L, and C4S were 2, 1, 2, and 1, respectively, then two structural 
genotypes were possible: AL/ AL-BS and AL-AL / BS. Given the large number of 
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structural genotypes possible (125 possible genotypes based on 15 structural 
haplotypes), in many individuals, more than 5 structural genotypes were consistent with 
a set of copy number data for C4 structural features. We therefore used the backbone 
SNP genotype data to estimate the likelihood of observing each structural genotype 
given a set of copy number as well as SNP genotype data. We provided a vector of 
genotype likelihoods (of length 125) as input for phasing in Beagle115 (version 4). Each 
structural genotype that was consistent with the copy number data was encoded as 
equally likely and those that were inconsistent were assigned a log10 likelihood of -1000 
(i.e., to indicate that they are extremely unlikely). We phased these likelihoods together 
with SNP genotypes and obtained posterior genotype probabilities for each possible 
structural genotype, for each individual. These probability estimates readily identified the 
most likely genotype for each individual (with a mean probability of 0.99).  
To test association between gene expression and clinical diagnosis, we used the 
Mann-Whitney (non-parametric) test. We specified the alternative hypothesis based on 
the direction of effect of C4 structural variation on gene expression and on the risk of 
schizophrenia – given that C4 structural variants associating to increased risk of 
schizophrenia also associated to higher expression, we hypothesized that the 
expression of C4 (as well as other genes that function in the early steps of the 
complement pathway, C1QB, C2, and C3) would be higher in patients with 
schizophrenia compared to unaffected controls, and that the expression of CSMD1 
(which promotes degradation of C4), would be lower in patients with schizophrenia. In 
order to test whether the expression of C4A associated with clinical diagnosis 
independently of structural variation in C4, we took the residuals from fitting expression 
to C4A and C4L copy number in a linear model and performed a Mann-Whitney test to 
assess for differences in these residuals between patients with schizophrenia and 
unaffected controls.  
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Description of case-control samples analyzed from the Psychiatric Genomics 
Consortium (PGC) 
A detailed description of the samples analyzed from the Psychiatric Genomics 
Consortium (PGC) data set is available elsewhere22 and details of the cohorts, their 
sample sizes, and SNP genotyping arrays used are provided in Supplemental table 2.  
Of the 49 cohorts from the PGC, we analyzed 40 case-control cohorts of European 
ancestry for which we had data available. Relatedness among samples and population 
structure was analyzed by the PGC Statistical Analysis Working Group, using a set of 
19,551 autosomal SNPs across all cohorts, removing one member of each pair with π ̂ > 
0.2. The first twenty principal components were tested for association to phenotype and 
ten of these were included as covariates in all of the association analyses (as described 
below).  
The Swedish cohort analyzed for copy number of C4A, C4L, and C4S using 
ddPCR includes samples from 2 of the 40 PGC cohorts listed in Supplemental table 2 
(scz_swe1_eur and scz_s234_eur). All subjects in this cohort were born in Sweden, and 
cases were defined based on a diagnosis of schizophrenia on two separate 
hospitalizations. Control subjects were matched by age, sex and county of residence 
and did not have a hospitalization with a psychiatric diagnosis.  
  
Quality control 
The SNPs and individuals retained for association analysis were subject to the 
following quality control (QC) parameters by the PGC Statistical Analysis Group 
included22: (i) SNP missingness < 0.05 (before sample removal); (ii) subject missingness 
< 0.02; (iii) autosomal heterozygosity deviation (|Fhet| < 0.2); (iv) SNP missingness < 0.02 
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(after sample removal); difference in SNP missingness between cases and controls < 
0.02; and SNP Hardy-Weinberg equilibrium (p > 10−6 in controls or P > 10−10 in cases).  
In addition to the above parameters that were analyzed on a genome-wide scale, 
we applied the following QC filters to the SNP genotype data from the extended HLA 
locus in each of the 40 cohorts analyzed. We removed three additional sets of SNPs: (i) 
those that were within the duplicated C4 locus (chromosome 6:31939608-32014384, hg 
19); (ii) SNPs whose allele frequency differed by more than 0.15 from their frequency in 
our HapMap CEU reference panel for imputation; and (iii) transversion SNPs (A/T and 
G/C) whose minor allele frequency was greater than 0.35 (as it can be problematic to 
determine whether they have the same strand assignment as SNPs in the reference 
panel for imputation).  
 
Imputation of C4 structural variation and expected C4A expression in the brain 
  We utilized the HapMap CEU reference panel created in Chapter 2 for imputation 
of C4 structural variation, using Beagle115. We imputed separately into each of the 40 
cohorts in the PGC data set. Our reference panel consisted of 111 unrelated individuals, 
with C4 structural variants on haplotypes with HapMap phase III SNPs in the extended 
HLA locus (chromosome 6: 25 - 34 Mb). The encoding of C4 structural variation in this 
reference panel was based on both the C4 structure as well as its HLA haplotype 
background (Chapter 2, Figure 2.10). C4 structures that segregated on different HLA 
SNP haplotypes were encoded as separate alleles in the reference panel – AL-AL 
structures were divided into two alleles, AL-AL 1 and AL-AL 2, based on which of the two 
HLA haplotypes they segregated on; AL-BL structures into three alleles that were based 
on the three well-defined haplotypes backgrounds and a fourth allele to represent the 
remaining set of poorly-defined haplotypes; and AL-BS structures into six alleles (five of 
which had well-defined haplotype backgrounds).  
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This strategy enabled us to independently test association to each of these 
imputed alleles and evaluate the extent to which the HLA haplotype on which C4 
structures segregated influenced their association to schizophrenia. This strategy also 
allowed us to (i) infer copy number of C4 structural features (C4A, C4B, C4L, and C4S) 
based on the C4 alleles imputed in each individual (e.g., an individual with C4 alleles AL-
AL 1 and AL-BL 2 has a diploid copy number of 3 for C4A, 1 for C4B, 4 for C4L and 0 for 
C4S); and (ii) infer expected expression of C4A in the brain, which we estimated as the 
copy number of C4A + copy number of C4L in each individual. This was based on the 
nearly identical effect size per copy of C4A and C4L that we calculated from regressing 
C4A expression in postmortem human brain tissue against copy number of C4A and 
C4L in a joint linear model. 
We imputed C4 structures into the Swedish cohort by making use of the copy 
number data generated for C4A, C4L, and C4S from ddPCR, together with the SNP 
genotype data from the HLA locus for each subject in the data set, as described above 
for the imputation of C4 structures into the SMRI samples.  
  
Molecular analysis of C4 copy number in the Swedish case-control cohort 
 We measured copy number of C4A, C4L, and C4S in 2,195 cases and 2,485 
controls of Swedish ancestry using ddPCR. Reaction conditions for ddPCR assays are 
provided in Chapter 2 and sequences of primers and probes used are available in 
Supplemental table 1.  Quality control parameters for inclusion of ddPCR measurements 
in the analysis were as described in Chapter 3.  
 
Testing association of C4 and SNPs to schizophrenia  
We performed a mega-analysis that utilized individual-level genotype data from all 
40 cohorts that we analyzed from the PGC data set. We tested association in a logistic 
112 	  
regression framework that included study indicator variables to account for cohort-
specific effects and principal components to control for population stratification:  
  log (oddsi) = βj x (dosei,j) + β!"!!! c x (cohorti,c) + β!"!!! p x (PCi,p) + θ 
where dosei,j is the number of chromosomes (0, 1, or 2) in each individual, i, that carried 
a C4 structural allele, j and βj is the additive effect per copy of the C4 allele. 39 study 
indicator variables (the number of cohorts minus 1) were included, with cohorti,c equal to 
1 if the ith individual belonged to the cth cohort and equal to 0 otherwise. In addition, ten 
principal components that associated to phenotype were included as covariates, with 
PCi,p being the pth principal component for the ith individual. We used the same 
framework for testing association to (i) individual SNPs, where dosei,j was the dosage of 
the minor allele, j, of the SNP in individual i; (ii) copy number of C4 structural features, 
where dosei,j was the diploid copy number of the C4 feature in individual i; and (iii) 
expected expression of C4A, where dosei,j was the number of copies of C4A + number of 
copies of C4L in individual i. To test association to C4 conditional on rs13194504, we 
included the dosage of that SNP as an additional covariate in the model.  
We obtained an estimate of effect size for a C4 structure (e.g., AL-AL) across all 
alleles that contained that given structure (e.g., AL-AL 1 and AL-AL 2), by performing an 
inverse variance meta-analysis based on the effect size and standard error associated 
with each C4 allele that contained the given C4 structure.  
  
In vitro assays of human CNS cells  
Primary human cortical neurons, astrocytes, and oligodendrocyte precursor cells 
were obtained from Sciencell Research Laboratories (catalog no. 1520, 1800, and 1600, 
respectively). The neurons were characterized by Sciencell to be immunopositive for 
MAP2, neurafilament, and beta-tubulin III; astrocytes, for GFAP; and oligodendrocyte 
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precursor cells for A2B5 and nestin. Primary human microglia, which expressed CD45, 
CD14, and CD68, were obtained from Clonexpress, Inc. (catalog no. HMG 030).  
Neurons were cultured on poly-L-lysine (PLL) coated plates in neuronal medium, 
(Sciencell, catalog no. 1521) which contained basal medium, neuronal growth 
supplement, and penicillin/streptomycin solution. Astrocytes were cultured on PLL-
coated plates in astrocyte medium (Sciencell, catalog no. 1801), which contained basal 
medium, fetal bovine serum, astrocyte growth supplement, and penicillin/streptomycin 
solution. Oligodendrocyte precursor cells were grown on PLL-coated plates in 
oligodendrocyte precursor cell medium (Sciencell, catalog no. 1601-b), and then 
differentiated into oligodendrocytes in oligodendrocyte precursor cell differentiation 
medium (Sciencell, catalog no. 1631). Microglia were cultured in 50:50 DMEM: F-12 
supplemented with 5% FBS and 10 ng/ml of M-CSF. RNA was extracted from these 
cells using the RNeasy micro kit (Qiagen) and gene expression analysis was done using 
RT-ddPCR.  
Copy number of C4 structural features in these cells was determined by ddPCR. 
The neurons, microglia, and oligodendrocyte precursor cells used in these experiments 
each had the following C4 copy number profile: 2 copies of C4A, 2 of C4B, 3 of C4L, and 
1 of C4S, and the astrocytes had a copy number of 2 for each of the C4 structural 
features.  
LPS from Escherichia coli 026:B6 (Sigma, catalog no. L2654-1MG) and poly(I:C) 
(Sigma, catalog no. P9582) were added to primary microglia after the cells had been 
grown in culture for 4 days. To test the effect of duration of treatment with LPS or 
poly(I:C) on gene expression, the reagent was added at different time points to each well 
and RNA was harvested at the same time so as to control for the length of time the cells 
were in culture.  
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Analysis of C4 expression in the BrainSpan data set 
We analyzed expression of C4 across developmental ages using the publicly 
available BrainSpan data set140. This data set includes transcriptome-wide gene 
expression measurements using RNA-sequencing analysis from up to sixteen brain 
regions across the course of pre- and postnatal human brain development. We analyzed 
expression of the gene annotated as C4A in this data set, but given that the C4A and 
C4B paralogs share more than 99% nucleotide identity, the measurements from RNA-
sequencing analysis reported for C4A would have included reads originating from either 
paralog. In addition, because the measurement at each developmental stage was from a 
different individual, the expression measurements are not corrected for variation in gene 
copy number across samples. In order to reduce the noise in the data, we calculated 
median measurements of expression for developmental ages that had data from multiple 
samples.  
  
Mice   
C57BL/6 wild type mice were used for profiling C4 expression in the brain across 
developmental ages. The generation of the C4 -/- mice that were used to investigate 
synapse elimination in the retinogeniculate system is described in detail elsewhere153. In 
these mice, the sequence spanning part of exon 23 through exon 29 has been replaced 
with a PGK-Neo gene. To generate transgenic mice with human C4, a BAC clone 
(CH501-116M5) containing the human C4AL and C4BL genes was obtained from the 
Children's Hospital Oakland Research Institute (CHORI). Circular BAC DNA was purified 
from 500-ml culture by cesium chloride gradient centrifugation. BAC DNA was linearized 
by digestion with PI-SceI and applied to a Sepharose CL-4B column in injection buffer 
(0.1 M NaCl, 10 mM Tris (pH 7.5), 0.1 mM EDTA). The DNA was diluted with injection 
buffer at 0.5 ng/µl and then microinjected into the pronuclei of fertilized eggs harvested 
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from FVB mice. Transgenic founder mice were screened by PCR using the C4A-specific 
primers 5′- GCTCACAGCCTTTGTGTTG -3′ and 5′- CTGCATGCTCCTGTCTAAC -3′ 
and the C4B-specific primers 5′- GCTCACAGCCTTTGTGTTG -3′ and 5′- 
CTGCATGCTCCTATGTATCTC -3′. We used ddPCR to determine copy number of 
human C4A, C4B, C4L and C4S in these mice.  
  
Analysis of dorsal lateral geniculate nucleus (dLGN) in mice 
Visualization and analysis of RGC synaptic inputs in the mouse dLGN was 
performed as described141. Cholera toxin-β subunit (CTB) conjugated to Alexa 488 
(green label) and CTB conjugated to Alexa 594 (red label) were intraocularly injected 
into the left and right eyes, respectively, of P9 mice, which were sacrificed the following 
day. Images were acquired using the Zeiss Axiocam and quantified blind to experimental 
conditions and compared to age-matched littermate controls. The degree of left and right 
eye axon overlap in dLGN was quantified using an R-value analysis as described143. 
Pseudocolored images representing the R-value distribution were generated in ImageJ. 
P-values were calculated from a Mann-Whitney test with an alternative hypothesis of 
higher R-value variance in wild type compared to C4 heterozygotes or C4 -/-; higher in 
C4 heterozygotes compared to C4 -/-; higher in C4 transgenic mice compared to C4 -/-.  
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In this thesis, we have developed approaches for characterizing complex forms 
of genome structural variation and for evaluating their contribution to phenotypes. We 
have applied these approaches toward investigating the genome's strongest influences 
on the risk of two common diseases that have been identified from genome-wide 
association studies. Specifically, we 
(i) unraveled the various structural forms of the C4 locus using novel molecular and 
statistical approaches;  
(ii) enabled analysis of C4 structural variation by imputation, and thereby, made it 
possible to investigate its contribution to phenotypes in large case-control cohorts using 
existing SNP genotype data; 
(iii) conducted the first imputation-based association analysis of complex structural 
variation in investigating the contribution of C4 to SLE, and found that increased copy 
number of C4A associated to lower disease risk;  
(iv) related variation in C4 structure to gene expression in lymphoblastoid cells lines, and 
found that the four common structural forms of C4 associated to C4A expression in 
proportion to the number of copies of C4A they contained, and associated to SLE risk in 
a manner that mirrored their effect on gene expression;  
(v) exploited the recurrence of C4 structures on multiple HLA haplotype backgrounds to 
develop a novel form of association testing and showed that the association of SLE to 
C4 is unlikely to be a result of correlation with genetic variation elsewhere in HLA locus;  
(vi) investigated the contribution of C4 structural variation to risk of schizophrenia in the 
largest case-control study to date of this disease (totaling > 60,000 individuals), and 
found that an allelic series of structural variants in C4 influences the risk of 
schizophrenia in a manner predicted by its effect on C4A expression in the brain; and 
(vii) identified a biological process, synaptic pruning, to which C4 contributes in the 
nervous system and could potentially underlie its association to schizophrenia.   
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 Previous studies investigating the association of C4 to phenotypes60, 154 have 
typically tested for differences in distribution of copy number between cases and 
controls, and/or evaluated the effect of deviation from a reference copy number (e.g., 
diploid copy number of 2). In contrast, the imputation and association strategy that we 
developed in this thesis enabled us to exploit the rich reservoir of genetic variation in the 
C4 (and surrounding HLA) locus to evaluate association in multiple ways, taking into 
account variation in diploid copy number, variation in structure of the C4 locus on a per-
chromosome level, and variation in the HLA haplotype on which each C4 structure 
segregates.  
It has been suggested that large-scale deep-sequencing studies will be required 
to find allelic series that help to identify genes with a causal influence on disease risk 
and to explore their biology11. Our findings indicate that the investigation of loci that 
segregate in several structural forms can be an additional strategy for identifying such an 
allelic series.  
A theme of yin and yang characterizes some of the main findings from this thesis. 
First, the segregation of common C4 structures on multiple HLA haplotypes limited the 
accuracy with which they could be captured by imputation. However, this very property 
also enabled a novel form of association testing and provided additional power to 
evaluate independence of effects within the HLA locus. Second, we found that structural 
variation in C4 contributed to the risk of SLE and schizophrenia with largely opposite 
directions of effect – the C4 structure associated with the highest risk of SLE was 
protective in schizophrenia, and vice versa. The presence of multiple structures that 
segregate at a common frequency raises the question of whether balancing selection 
involving SLE and schizophrenia (and potentially other phenotypes) could have 
contributed to the high degree of polymorphism at the C4 locus.  
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The apparent antagonistic influence that C4 structural variation seems to have on 
the risk of SLE and schizophrenia does not necessitate that potential therapeutic options 
that could eventually be developed based on these findings should have a zero-sum 
impact with respect to these phenotypes. A greater opportunity for building a therapeutic 
armamentarium might exist in viewing C4 and other genes implicated in disease not just 
as potential drug targets themselves, but as sentinels pointing to biological processes 
(e.g., synaptic pruning) or cell types (e.g., microglia, a key cell type involved in synaptic 
pruning) that may be relevant do a disease.  
  
Future directions 
  The findings from this thesis motivate several additional studies, some of which 
are discussed here.  
First, the HLA locus associates to dozens of phenotypes, for most of which the 
gene(s) and functional allele(s) driving the association have not been identified. The 
reference panels and imputation strategy developed in this thesis enable the 
investigation of whether C4 contributes to these phenotypes in the context of association 
to HLA SNPs and classical alleles. In particular, phenotypes associating to HLA-
DRB1*03:01 may represent strong candidates to prioritize, given the high degree of 
linkage disequilibrium between this allele and the BS structure of C4.  
Second, the results from Chapter 2 suggest that it is possible to analyze complex 
forms of structural variation using imputation. However, the extent to which this applies 
to structurally complex loci elsewhere in the genome remains to be investigated. To this 
end, a map of genomic loci harboring complex and multi-allelic forms of structural 
variation will be fruitful. Such a map may be generated using computational algorithms 
for discovering and genotyping structural variants from whole-genome sequencing 
data85. This will enable investigation of how such loci vary in structure across human 
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populations, how this variation relates to flanking SNP haplotypes, and whether it can be 
captured using imputation.  
Third, our findings in Chapter 3 revealed that increased copy number of C4A is 
associated with a lower risk of SLE. However, complement proteins have been 
implicated in causing tissue damage during the inflammatory phase of the disease102. 
Therefore, while C4 may be protective against developing SLE, it may contribute to the 
disease pathology after its onset. This possibility can be investigated by examining 
whether C4 structural variation associates to incidence or severity of specific clinical 
manifestations of the disease, such as lupus nephritis, within SLE patients. The findings 
from such studies could have important therapeutic implications – if C4 is protective 
against the overall risk of developing SLE but contributes to disease pathology after its 
onset, potential pharmacologic interventions in SLE patients would be aimed at reducing 
activity of C4, rather than potentiating it.  
Fourth, our results indicate a differential contribution of C4A and C4B, which are 
more than 99% identical at the nucleotide level, to SLE risk. While C4A copy number 
associated to SLE, C4B copy number did not independently contribute to disease risk. 
These findings may reflect differences in biochemical properties of these two 
paralogs108, and are consistent with C4A having a higher affinity for immune complexes 
and C4B, for carbohydrate antigens. A better understanding of the role of these paralogs 
could come from studies in mice. For example, C4 -/- mice that are reconstituted with 
either the human C4A or C4B gene could be analyzed for whether the two paralogs 
have a differential ability to rescue a lupus-like phenotype.  
Fifth, a better understanding of the functional impact of the HERV sequence in 
C4 may be gained through studying transgenic mice that carry a human C4 gene with or 
without the HERV insertion (in a mouse C4 -/- background). These mice can be analyzed 
qualitatively as well as quantitatively, to investigate whether there is (i) variation in the 
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cell types and brain structures in which C4 is expressed; (ii) variation in the temporal 
pattern of C4 expression in the brain across developmental stages; and (iii) an influence 
of the HERV sequence on the quantitative levels of C4 expression (as we found in 
postmortem human brain tissue).  
Sixth, our studies of the retinogeniculate system in C4 -/- mice and transgenic 
mice with human C4 revealed that C4 contributes to synaptic pruning in this system. A 
recapitulation of the allelic series of human C4 structural variants in mice would enable 
investigation of whether the specific structural alleles of human C4 that associate to 
schizophrenia differ with respect to their ability to rescue the pruning phenotype in C4 -/- 
mice. In addition, these mice can be analyzed for pathological changes seen in 
postmortem brains from patients with schizophrenia, such as thinning of the cortex and 
reduction in dendritic spine density136. Furthermore, these mice could also be subject to 
behavioral analyses to investigate whether structural variation in C4 contributes to such 
phenotypes. 
We hope that the approaches presented in this thesis will enable investigation of 
other structurally complex loci in the human genome and their contributions to 
phenotypes, and that our findings implicating C4 in SLE and schizophrenia will motivate 
additional functional studies to gain biological insights into these diseases.  
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Supplemental Table 1. Primer and probe sequences. All sequences are provided in the 
5’ to 3’ orientation.   
*, Assays were based on Wu et al.109  
 
Assay Forward Primer Reverse Primer Probe 
Copy number of human C4A* 
CCTTTGTGTTGAAG
GTCCTGAGTT 
TCCTGTCTAACACTG
GACAGGGGT 
VIC-
CCAGGAGCAGGTAGGAGGC
TCGC-MGB 
Copy number of human C4B* 
TGCAGGAGACATCT
AACTGGCTTCT 
CATGCTCCTATGTAT
CACTGGAGAGA 
VIC-AGCAGGCTGACGGC-
MGB 
Copy number of human C4L* 
TTGCTCGTTCTGCTC
ATTCCTT 
GTTGAGGCTGGTCCC
CAACA 
VIC-
CTCCTCCAGTGGACATG-
MGB 
Copy number of human C4S* 
TTGCTCGTTCTGCTC
ATTCCTT 
GGCGCAGGCTGCTG
TATT 
VIC-
CTCCTCCAGTGGACATG-
MGB 
Control for copy number assays 
of human DNA (RP1)* 
GACCAAATGACACA
GACCTTTGG 
GACTTTGGTTGGTTC
CACAAGTC 
FAM-AGGGACTCAGAA 
ATCACGT 
Control for copy number assays 
of human DNA (RPP30) 
GATTTGGACCTGCG
AGCG 
GCGGCTGTCTCCACA
AGT 
FAM-CTGACCTGAAGGCTCT-
MGB 
Control for copy number assays 
of human DNA (Ultraconserved 
element) 
GCTATAATAGAAGG
GGGAAGTCG 
ATTGTGGGCCTGTTT
TGAAT 
FAM-
ATTGCGTCGCTCTGAGCCC
C 
Control for copy number assays 
of mouse DNA (Rpp30) 
TGACCCTATCAGAG
GACTGC 
CTCTGCAATTTGTGG
ACACG 
FAM-
TGGGCTTTCTGAAAATGATG
GCAA 
Long-range PCR assay spanning 
intron 9 to exon 26 (to amplify 
sequences defining the L/S and 
A/B structural features from all 
C4 genes) 
TTGCTCGTTCTGCTC
ATTCCTT 
CAATGGCTCTGCACC
CTCAT 
 Long-range PCR assay spanning 
intron 9 to exon 26 (to amplify 
sequences defining the L/S and 
A/B structural features from C4A 
genes) 
TTGCTCGTTCTGCTC
ATTCCTT 
TCCTGTCTAACACTG
GACAGGGGT 
 
Expression of human C4A 
CCTGAGAAACTGCA
GGAGACAT 
GTGAGTGCCACAGTC
TCATCAT 
FAM-
CAGGACCCCTGTCCAGTGT
TAGAC 
Expression of human C4B 
CCTGAGAAACTGCA
GGAGACAT 
GTGAGTGCCACAGTC
TCATCAT 
FAM-
CTATGTATCACTGGAGAGAG
GTCCTGGAAC 
Expression of human C1QB 
CTCACTCTACCCCC
AACACC 
TTCACTCAGCAGCAT
TCACC 
FAM-
ACCCCTTGCCCAACCAATGC 
Expression of human C2 
CTCCATCTTCTACCT
CTGAATGG 
AGAGACCCGGATTTA
CTCAGC 
FAM-
CACCCTTAGACCCTGTGATC
CATCCT 
Expression of human C3 
GTTGGAGGGACACA
TCAAGG 
CTCTACCCAGGCCAC
CTTC 
FAM-
TGGTGTTCCAAGCCTTGGCT
CA 
Expression of human CSMD1 
GCAAGTCTGGCTTC
TCCATC 
ATTTTGGGGCATACC
TGGAT 
FAM-
CCACCTCAATTGCAGCCACC
TG 
Expression of mouse C4 
AGCCTGTTTCCAGC
TCAAAG 
GTCCTAAGGCCTCAC
ACCTG 
FAM-
CCCCGGCTGCTGAACTCCA
T 
Control for expression assays of 
human RNA (NUDCD3) 
AGTCCTGTGACCAG
GTGTAGTTC 
CAGGAGCAGTTCCAG
AAAAATC 
HEX-
TCGGACAGCACCATTGTAAC
TGTCG 
Control for expression assays of 
mouse RNA (Eif4h) 
GTGCAGCTTGCTTG
GTAGC 
GTAAATTGCCGAGAC
CTTGC 
VIC-
AGCCTACCCCTTGGCTCGG
G 
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Supplemental Table 2. Case-control cohorts analyzed from the Psychiatric Genomics 
Consortium (PGC) data set. The details presented in this table are from the latest PGC 
manuscript,22 where additional information about these cohorts can be found. Cohort 
name indicates the name of the cohort in the PGC databases. PMID is the PubMed ID 
number for the initial report on that study, where available.  
Cohort name PMID  Site 
Genotyping 
array 
Number 
of cases 
Number 
of 
controls 
scz_aarh_eur 19571808 Denmark Illumina 650K 876 871 
scz_aber_eur 19571811 Aberdeen, UK Affymetrix 6.0  719 697 
scz_ajsz_eur 24253340 Israel  Illumina 1M 894 1594 
scz_asrb_eur 21034186 Australia Illumina 650K 456 287 
scz_boco_eur 19571808 
Bonn/Mannheim, 
Germany Illumina 550K 1773 2161 
scz_buls_eur 
 
Bulgaria Affymetrix 6.0  195 608 
scz_cati_eur 18347602 US (CATIE) 
Affymetrix 
500K 397 203 
scz_caws_eur 19571811 Cardiff, UK  
Affymetrix 
500K 396 284 
scz_cims_eur 
 
Boston, US 
(CIDAR) 
Illumina 
OmniExpress 67 65 
scz_clm2_eur 22614287 UK (CLOZUK) Illumina 1M 3426 4085 
scz_clo3_eur 22614287 UK (CLOZUK) 
Illumina 
OmniExpress 2105 1975 
scz_cou3_eur 21850710 
Cardiff, UK 
(CogUK) 
Illumina 
OmniExpress 530 678 
scz_denm_eur 19571808 Denmark Illumina 650K 471 456 
scz_dubl_eur 19571811 Ireland Affymetrix 6.0  264 839 
scz_edin_eur 19571811 Edinburgh, UK Affymetrix 6.0  367 284 
scz_egcu_eur 15133739 Estonia (EGCUT) 
Illumina 
OmniExpress 234 1152 
scz_ersw_eur 19571808 Sweden (Hubin) 
Illumina 
OmniExpress 265 319 
scz_fi3m_eur 19571808 Finland Illumina 317K  186 929 
scz_fii6_eur 
 
Finnish Illumina 550K 360 1082 
scz_gras_eur 20819981 Germany (GRAS) 
Affymetrix 
Axiom  1067 1169 
scz_irwt_eur 22883433 Ireland (WTCCC2) Affymetrix 6.0  1291 1006 
scz_lacw_eur 22885689 
Six countries, 
WTCCC controls Illumina 550K 157 245 
scz_lie2_eur 11381111 NIMH CBDB 
Illumina Omni 
2.5M 133 269 
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Supplemental Table 2 (continued) 
 
 
Cohort name PMID  Site 
Genotyping 
array 
Number 
of cases 
Number 
of 
controls 
 
scz_lie5_eur 11381111 NIMH CBDB Illumina 550K 497 389 
scz_mgs2_eur 19571809 
US, Australia 
(MGS) Affymetrix 6.0  2638 2482 
scz_msaf_eur 20489179 
New York, US & 
Israel Affymetrix 6.0  325 139 
scz_munc_eur 19571808 Munich, Germany Illumina 317K  421 312 
scz_pewb_eur 23871474 
Seven countries 
(PEIC, WTCCC2) Illumina 1M 574 1812 
scz_pews_eur 23871474 
Spain (PEIC, 
WTCCC2) Illumina 1M 150 236 
scz_port_eur 19571811 Portugal Affymetrix 6.0  346 215 
scz_s234_eur 23974872 Sweden (sw234) Affymetrix 6.0  1980 2274 
scz_swe1_eur 23974872 Sweden (sw1) Affymetrix 5.0 215 210 
scz_swe5_eur 23974872 Sweden (sw5) 
Illumina 
OmniExpress 1764 2581 
scz_swe6_eur 23974872 Sweden (sw6) 
Illumina 
OmniExpress 975 1145 
scz_top8_eur 19571808 Norway (TOP) Affymetrix 6.0  377 403 
scz_ucla_eur 19571808 Netherlands Illumina 550K 700 607 
scz_uclo_eur 19571811 London, UK Affymetrix 6.0  509 485 
scz_umeb_eur 
 
Umeå, Sweden 
Illumina 
OmniExpress 341 577 
scz_umes_eur 
 
Umeå, Sweden 
Illumina 
OmniExpress 193 704 
scz_zhh1_eur 17522711 New York, US 
Affymetrix 
500K 190 190 
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